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"You only see what you are looking for and you only look for what you know" 
 
Patrick Walsh

  
ABSTRACT 
Background: Urinary incontinence is a significant long-term complication after radical 
prostatectomy. The aim was to evaluate clinically significant definitions of urinary 
incontinence and to investigate its potential predictors. Robot-assisted radical prostatectomy 
has become a widespread surgical technique in prostate cancer despite the lack of randomised 
trials showing its superiority compared to open surgery. A further aim was to compare short-
term results three months after the two surgical techniques.  
Material and methods: Data for this thesis derives from two sources. The first cohort is a 
consecutive series of 1411 men who underwent radical prostatectomy at Karolinska 
University Hospital from 2002 to 2006 and completed a study-specific validated 
questionnaire. The second cohort derives from the LAPPRO study, a multicentre, prospective 
controlled trial of men who underwent radical prostatectomy between 2008 and 2011 
(n=4003). Data was collected prospectively with validated patient questionnaires and case 
report forms which were completed by health-care personnel.   
Results: Urinary leakage as a long-term side effect after radical prostatectomy proved to 
cause the patient a lot of bother. Even a proportion of those who had occasional leakage 
reported significant bother. Increased age at surgery increases the risk of urinary incontinence 
one year after surgery and this increases exponentially with age. Furthermore patients with 
preoperative urinary leakage have an increased risk of postoperative incontinence. When 
evaluating short-term outcomes and comparing open radical prostatectomy to robot-assisted 
radical prostatectomy, re-operation during initial hospital stay was more frequent after open 
surgery. Men operated by open surgery also sought medical care more frequently compared 
to men operated by robot-assisted surgery within three months after surgery. Men who 
underwent lymph-node dissection proved to have an increased risk for readmission as well as 
a greatly increased risk for thromboembolic events, such as deep venous thrombosis and 
pulmonary embolism. Regardless of whether lymph-node dissection was preformed or not, 
men who underwent open prostatectomy appeared to have an increased risk of 
thromboembolic events compared to those who had robot-assisted surgery. 
Conclusions: If the definition of continence consists of the use of pads, a certain number of 
men that are bothered significantly by urinary leakage will be defined as continent. When 
planning a patient for radical prostatectomy, one must take age and preoperative urinary 
leakage into consideration as risk factors for postoperative incontinence. The robot-assisted 
radical prostatectomy is a safe procedure and has some short-term advantages compared to 
open surgery. Lymph-node dissection during radical prostatectomy increases the risk for 
thromboembolic events, the risk is higher in open surgery compared to robot-assisted surgery. 
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1 INTRODUCTION 
Hippocrates, the father of western medicine, once stated “Primum, non nocere” - “First, do no 
harm”. Today this statement is still highly relevant in the surgical treatment of prostate 
cancer. Studies have shown that we have to operate on eight men to prevent one from dying 
from prostate cancer.1 Currently there is a substantial overtreatment of prostate cancer as we 
have little understanding of which prostate cancers will lead to death. The operation, in turn, 
can lead to life-long side effects such as urinary incontinence and impotence, and the risk of 
overtreatment must be weighed up against the risk of complications.  
In light of "First, do no harm", the overall objective of this thesis was to investigate the harm 
that we cause the patient by performing prostate cancer surgery. As urinary incontinence is a 
common long-term complication after radical prostatectomy, we wished to identify patients at 
risk of this complication as well as quantify its effect on patient morbidity. Secondly we 
evaluated whether short-term complications could be reduced by the use of a new surgical 
technique. 
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2 BACKGROUND 
2.1 PROSTATE CANCER 
2.1.1 Epidemiology 
In 1853 the English surgeon J. Adams was the first to describe a case of prostate cancer and 
he concluded his report with the words "a very rare disease".2 Today prostate cancer is the 
most common type of cancer in Sweden, followed by breast cancer, skin cancer and colon 
cancer.3 About one third of all cancers in men are prostate cancer and the probability of 
developing prostate cancer is 13% before 75 years of age.4 
2.1.1.1 Incidence 
In Sweden, 9663 men were diagnosed with prostate cancer in 2012.3 In the US there were 
238,590 estimated new cases in 2013 (28% of all cancers), accounting for the most common 
cancer in men before lung and colorectal cancers.5 When the measurement of prostate-
specific antigen (PSA) became more common there was a substantial increase in the 
incidence of prostate cancer in the US.6 The incidence peaked in 1992 approximately 5 years 
after the introduction of PSA screening. The increased use of PSA in diagnosis of prostate 
cancer led to many clinically non-significant prostate cancers being diagnosed. It has been 
shown that about 30% of men in their 60s and in 50% of men in their 80s have prostate 
cancer when performing microscopic examination during autopsy or cysto-prostatectomy for 
bladder cancer in men without a history of prostate cancer.7 There was a sharp decrease in 
incidence after the peak in 1992 (4.4% per year between 2001 and 2005) which may reflect a 
stabilisation of PSA-testing or that many of the latent cancers already had been detected. 
The incidence of prostate cancer varies widely between different parts of the world and 
between different ethnicities, disease rates differ by more than 100-fold between populations. 
Prostate cancer is most common among Black Americans (272 cases per 100,000), second 
most common among White Americans and Scandinavians, while the disease is unusual in 
Southeast Asia (1.9 cases per 100,000 in China).8 This pattern suggests that life-style factors 
and heredity play a role in the development of prostate cancer. It has been shown that men 
with germ line mutations in breast cancer genes BRCA1 and BRCA2, have an increased risk 
of prostate cancer.9,10 Both incidence and mortality are higher in Black Americans compared 
to White Americans.11 This has been attributed to the acculturation of Black Americans into 
US White society.12 However, research suggests that Black Americans receive less 
aggressive therapy.13 Other risk factors for prostate cancer that have been proposed are 
obesity, high intake of animal fat, red meat and dairy products; whilst a high intake of 
antioxidants and phytoestrogens such as tomatoes, cabbages, onions, soya beans and green 
tea appear to decrease the risk of prostate cancer.14,15,16 Certain medications such as aspirin, 
statins and metformin have also been suggested to reduce the risk of prostate cancer 
diagnosis.17,18,19 However, others have found no such association.20,21 The evidence have 
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thus not been strong enough to provide recommendations in order to prevent the 
development of prostate cancer.  
2.1.1.2 Mortality 
Mortality rates also vary widely across different countries and Sweden has among the highest 
morality rate in the world.22 Prostate cancer is the second most common cause of death in 
men in Sweden after cardiovascular death.23 The age-standardized mortality rate from 
prostate cancer has decreased over the last fifteen years. The decline has been most prominent 
in men under 75 years of around 35 percent. In contrast, the actual number of men who die of 
the disease every year in Sweden has been relatively stable at around 2,400 during the past 
decade. One reason is that the number of elderly men in the population increases with 
increasing life expectancy (Figure 1).24 
In the US there were 29,720 estimated deaths from prostate cancer in 2013. The death rates in 
the US have also been declining since the early 1990s and is the second most common cancer 
related cause of death after lung cancer.5  
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Figure 1. Prostate cancer incidence and mortality in Sweden between 1970 and 2012. 
Annual numbers of new prostate cancer cases and prostate cancer deaths per 100 000 
persons, crude rate.  
Graphical illustration: A Wallerstedt. Data adapted from NORDCAN Association of the 
Nordic Cancer Registries and the Swedish National Board of Health and Welfare. 
2.1.1.3 Survival rates 
The relative 5-year survival rate for prostate cancer is over 90 percent in Sweden today.4 The 
survival rates have increased significantly in all age categories in most recent years (Figure 
2). One reason for improved survival rates could be due to longer life expectancy, a further 
reason may be that men are diagnosed with a "latent" prostate cancer late in life through PSA 
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testing. Another reason could of course be the improvements in treatment and that nowadays 
cancers are treated that previously were considered too advanced to cure. Also in the US 
survival rates have markedly increased for prostate cancer with 5 year relative cancer survival 
rates from 68% in the years 1975-1977 to 99% in the years 2002-2008.5  
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Figure 2. Five year relative survival from prostate cancer in Sweden between 1964-2011. 
Graphical illustration: A Wallerstedt. Data adapted from NORDCAN Association of the 
Nordic Cancer Registries. 
2.1.2 Diagnosis 
Investigation of early detection of prostate cancer includes Digital Rectal Examination 
(DRE), Prostate-Specific Antigen (PSA) blood test, Trans-Rectal Ultrasound (TRUS), needle 
biopsy and in some cases imaging with Magnetic Resonance Imaging (MRI). 
2.1.2.1 Digital rectal examination (DRE) 
A digital rectal exam should always be performed when investigating lower urinary tract 
symptoms in men. The purpose of palpation is to estimate the size of the prostate and to 
identify palpable tumour lesions. However, DRE is a test with only fair reproducibility 
among urologists.25 Furthermore DRE misses a substantial proportion of cancers and detects 
the cancers often in a late stage. Studies have shown that an abnormal DRE has a sensitivity 
of 44%, a specificity of 68% and a positive predictive value of 46% for detecting prostate 
cancer on biopsies.26 The positive predictive value of DRE is improved by PSA-testing. If a 
suspected nodule is palpated it should be classified according to the TNM classification e.g. 
whether the tumour is confined within the prostate, extends through the prostatic capsule and 
if it is separated from the organs next to it (Table 1).27 
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T
TX
T0
T1a Tumour incident histological finding in 5% or less of tissue resected
T1b Tumour incident histological finding in more than 5% of tissue retracted
T1c Tumour identified by needle biopsy (eg because of elevated PSA)
T2a Tumour involves one half of one lobe or less
T2b Tumour involves more than half of one lobe, but not both lobes
T2c Tumour involves both lobes
T3a Extracapsular extension (unilateral or bilateral)
T3b Tumour invades seminal vesicles(s)
N Regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph nodes metastasis
N1 Regional lymph node metastasis
M Distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Non-regional lymph nodes(s)
M1b Bone(s)
M1c Other site(s)
Primary tumour
Primary tumour cannot be assessed
No evidence of primary tumour
T1
Clinically inapparent tumour not palpable or visible by imaging
T2
Tumour confined within prostate
T3
Tumour extends through the prostatic capsule
T4
Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, 
external sphincter, rectum, levator muscles, or pelvic wall
 
Table 1. TNM classification, seventh edition.27 
2.1.2.2 Prostate-specific Antigen (PSA) 
PSA is a protein produced in the prostate and secreted in high concentrations in the seminal 
fluid where it is involved in the liquefaction of the seminal coagulum.28 PSA circulates in 
serum both bound and unbound. The blood levels of PSA typically rises in a man with 
prostate cancer. However, some of the worst tumours deform the prostate cells to the extent 
that they are unable to produce PSA. The level of PSA also rises due to many other factors 
apart from cancer, thus an elevated PSA is not on its own a strong predictor for prostate 
cancer. Furthermore, there is no real cut-off point for PSA where the sensitivity and 
specificity rises. Studies have shown that the sensitivity for detecting prostate cancer is 
different for different cut-off points; PSA level of 1.1, 2.1, 3.1 and 4.1 ng/mL yielded 
sensitivities of 83.4%, 52.6%, 32.2% and 20.5% respectively and specificities of 38.9%, 
72.5%, 86.7% and 93.8% respectively.29 Other reasons for elevated PSA are age, benign 
prostate hyperplasia (BPH), urinary tract infection, urinary retention, renal failure and 
iatrogenic examinations of the urinary tract such as cystoscopy and TRUS with biopsies.  
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In conclusion, there are a lot of factors to consider when evaluating an elevated PSA and 
deciding whether to further investigate with trans-rectal ultrasound (TRUS) and biopsies. To 
help with this decision there are a number of factors with PSA that are significantly 
associated with prostate cancer aggressiveness such as the rate of change of PSA (PSA 
velocity and doubling time), the PSA density (serum PSA divided by prostate volume) and 
the percentage of PSA in the free or complex isoforms.30,31,32,33,34,35 In men with prostate 
cancer a greater proportion of the PSA is attached to macromolecules compared to men with 
only BPH. The higher the ratio, the lower the risk for prostate cancer.  
Screening with PSA has been widely debated and no country has yet introduced a national 
PSA-based screening program. However, many countries use frequent PSA testing 
'opportunistic screening' although it is currently unknown whether it reduces prostate cancer 
mortality or not. Recent results from the Göteborg Randomized Population-based Prostate 
Cancer Screening Trial showed that organized screening reduces prostate cancer mortality 
but is associated with overdiagnosis.36 
2.1.2.3 Trans-Rectal Ultrasound (TRUS) 
TRUS is performed to measure the size of the prostate, the shape (e.g. if there is a lobus 
tertius) and to detect areas suspicious for tumour or extra-prostatic growth. If the 
investigation raises suspicion of prostate cancer, needle biopsies are performed with TRUS 
under local anaesthesia. The recommendation in Sweden is to initially take 10-12 systematic 
biopsies from the peripheral zone where most cancers are located.24 The histopathology from 
the biopsy cores is then evaluated by the pathologist. More than 95% of all cancers in the 
prostate are acinic adenocarcinomas, the remaining 5% are represented by subtypes of 
prostate adenocarcinoma such as ductal, mucinous, small cell carcinoma, primary 
translational cell carcinoma and sarcoma.37 If the histopathology report is benign but there is 
a persisting clinical suspicion of prostate cancer, repeat biopsies are performed with 
additional cores from the transitional zone. 
2.1.2.4 Gleason score 
A grading system for the evaluation of prostatic adenocarcinoma was originally developed by 
Donald F. Gleason in 1966.38 It was based on the glandular pattern of the tumour at low 
magnification. This system categorises patterns into five different grades. The Gleason score 
is then expressed as a sum of the grade which occurs most frequently in the biopsy, and the 
highest grade that can be detected e.g. 3+4=7. The system has been modified several times in 
1967, 1974, 1977 and in 2005. The grading currently used is based on the latest modification 
done in 2005 by the ISUP International Society of Urological Pathology.39 Figure 3 describes 
the characteristics for each Gleason pattern. 
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Figure 3. 2005 ISUP Modified Gleason System39 
Pattern 1: Circumscribed nodule of closely packed but separate, uniform, rounded to oval, medium-
sized acini (larger glands than pattern 3) 
Pattern 2: Like pattern 1, fairly circumscribed, yet at the edge of the tumor nodule there may be 
minimal infiltration. Glands are more loosely arranged and not quite as uniform as Gleason pattern 1 
Pattern 3: Discrete glandular units. Typically smaller glands than seen in Gleason pattern 1 or 2. 
Infiltrates in and amongst non-neoplastic prostate acini. Marked variation in size and shape. Smoothly 
circumscribed small cribriform nodules of tumor 
Pattern 4: Fused microacinar glands, Ill-defined glands with poorly formed glandular lumina. Large 
cribriform glands. Cribriform glands with an irregular border. Hypernephromatoid. 
Pattern 5: Essentially no glandular differentiation, composed of solid sheets, cords, or single cells. 
Comedocarcinoma with central necrosis surrounded by papillary, cribriform, or solid masses. 
 
The Gleason score has a fairly good inter-observer reproducibility among uropathology 
experts, however not so good when compared to general pathologists.40,41,42 Berg et al. 
reports that a general and an expert uropathologist reports the same Gleason score (GS) in 
78% of cases.43 This highlights the need for using experts in the field of uropathology when 
evaluating histology in prostate biopsies since the urologist bases a great deal of the treatment 
decision (i.e. what kind of treatment, nerve-sparing surgery, lymphadenectomy and 
preoperative MRI or bone scintigraphy) on the pathology report. Data from the same study 
showed that there was an acceptable correlation between the grade of biopsy and the 
subsequent radical prostatectomy with 68% concordance. In the non-matched cases the GS 
was significantly higher in the prostatectomy specimens. Two thirds of men with GS = 6 had 
a higher GS in their prostatectomy specimen, however the level of agreement was higher in 
GS ≥ 7.43 The under-grading reflects the sampling error that can not be eliminated because 
biopsies only represent a small fraction of the prostate.44 Increasing the number of core 
biopsies taken increases the sample size, thus reducing this discrepancy. Currently in Sweden 
it is recommended to take 12 cores the first round of biopsies. 
The ultimate value of a grading system would be its prognostic capability. The Gleason score 
has been proven to have a strong correlation with prognosis of prostate cancer. In a register-
based nationwide cohort of over 12000 men with locally advanced prostate cancer (defined as 
local clinical stage T3, T4 or alternatively T2 with serum levels of PSA 50-99 ng/ml, without 
signs of metastases) the prostate cancer specific mortality at 8 years of follow-up was 28% 
for GS 2-6, 41% for GS 7, 52% for GS 8 and 64% for GS 9-10 without any treatment.45 An 
important cut-off in predicting prognosis with GS is Gleason pattern 4 and 5. These tumours 
are much more aggressive as compared to Gleason pattern 1-3 and this is reflected in a 
strongly increased risk for lymph-node metastases and death.46,47 High GS is also associated 
with higher risk of extra prostatic tumour extension.48 
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2.1.2.5 Magnetic Resonance Imaging (MRI) 
Over the past decade, imaging of prostate cancer has been developed and improved. MRI is 
used for diagnostic purposes to determine the stage of the disease in prostate cancer (T and N 
stage). However, there is currently no strong scientific evidence regarding the usefulness of 
MRI and whether it leads to increased survival. To detect prostate cancer multi-parametric 
MRI is needed which includes a combination of T2-weighted imaging, dynamic contrast-
enhanced MRI and diffusion-weighted imaging.49,50 Detection of highly differentiated 
cancers, i.e. with low Gleason grade, has lower sensitivity with MRI compared to the low 
differentiated cancers that should preferably be treated.51 There is a strong belief that MRI 
will have an increasing role in the staging of prostate cancer in the future. It could help 
provide even better knowledge of the localization of the tumour before the treatment decision 
is made and also guide how treatment for a specific patient should optimally be performed. 
To get a good sensitivity and specificity it is of great importance to have an experienced team 
of radiologists, urologists and pathologists with a high patient load. The latest use of MRI is 
in combination with trans-rectal ultrasound, where the MRI images are transferred to the 
ultrasound machine and linked to the ultrasound images in real time. This enables biopsies to 
be targeted towards suspicious areas visualised on MRI, thus allowing for fewer biopsies to 
be taken overall to detect prostate cancer. This technique is still under development but shows 
promising results compared to systematic biopsies in prostate cancer detection and might play 
an important role in the future.52  
2.1.3 Treatment options in localized prostate cancer 
In recent years, the number of diagnosed prostate cancer cases have increased significantly, 
partly due to expanded and improved diagnosis of prostate cancer with the introduction of 
PSA and partly because of the increased life expectancy of the population. This has led to 
more men today being offered curative treatment following early diagnosis when the cancer 
is still localized. PSA testing has resulted in lead-time bias, since cancers are detected about 9 
to 13 years earlier than previously.53 However, increasing numbers of harmless cancers will 
be diagnosed. The natural course of prostate cancer is unpredictable, and as a result clinicians 
are still today unable to differentiate between aggressive prostate cancer that poses a threat to 
the patient's life, and those cancers which are slow growing and will not affect the patient 
within his lifetime. A lot of biological and histological research is being done in the search 
for the prediction tumour behaviour.54  
However, we know today that there are a number of factors that predict prognosis and 
aggressiveness of the tumour. As mentioned previously the PSA level including the total 
PSA, the change of PSA over time and PSA ratio are significantly associated with the 
aggressiveness of the tumour. Furthermore certain information from the biopsy correlates 
with cancer aggressiveness. The Gleason score is the most important factor but also number 
of cores with cancer, the distribution and volume of cancer in the cores, the presence of 
perineural space invasion, lymphovascular invasion, or ductal or neuroendocrine 
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differentiation.45,55,56 To assist the urologist in the assessment of all these variables 
nomograms (prediction tables) have been developed.57 
Prostate cancer is considered incurable if: metastasis exists, PSA-level is above 100 ug/l, if 
there is wide spread lymph-node invasion, or the cancer is stage T4 with invasion of other 
organs except for the seminal vesicles. Untreated prostate cancer without metastasis is 
divided into four risk groups which are correlated with prognosis and will aid in the treatment 
decision (Table 2).58  
Risk Stage Grade PSA (ng/ml)
Very low risk T1c ! 6 <10
cancer in 1-4 of a total of 8-12 biopsy cores, 
maximum of 8 mm total cancer length in 8-12 
biopsy cores, PSA density <0.15 ug / l / cm3
Low risk T1-T2a ! 6 <10
Moderate risk T2b 7 10-19.9
High risk T2c-T3 8-10 " 20 GS 8-10 (or widespread growth of GS 4 + 3 = 
7  in more than half of all biopsy cores)
 
 
Table 2. Swedish national guidelines risk classification of prostate cancer58 
 
Curative treatment of localized prostate cancer consists of radiotherapy or surgery with 
radical prostatectomy. A Swedish randomized trial of radical prostatectomy, the SPCG-4 
study, showed that radical prostatectomy had an absolute risk reduction of 11% in mortality 
compared to watchful waiting.1 The awareness that radical prostatectomy improves survival 
has contributed to surgery becoming the most common form of treatment in Sweden. A third 
option for localized prostate cancers is active surveillance for patients with very low risk 
cancers which allows delayed primary treatment until monitoring shows any signs of cancer 
progression, thus avoiding "unnecessary" treatment. In the section below these three different 
treatments are described in more detail.  
2.1.3.1 Radical prostatectomy 
Radical prostatectomy was the first treatment for prostate cancer and it has been performed 
for over 100 years.59 The operation involves removal of the prostate gland and seminal 
vesicles and in more advanced cases also includes removal of the lymph-nodes that drain the 
prostate. It is a technically difficult operation to perform due to its inaccessible location in the 
small pelvis. Despite this the radical prostatectomy is today the gold standard treatment for 
localized prostate cancer.60 Radical prostatectomy as primary treatment of prostate cancer has 
increased over the latest decades in Sweden, mostly since the introduction of PSA which led 
to an increase in the incidence of mainly localized cancers which are curable. Figure 4 shows 
the total number of radical prostatectomies as primary treatment in Sweden between 1998 
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and 2013. The reason for the decline since around 2010 is believed to be due to more patients 
with low-risk cancers being put on active surveillance instead of treatment with radical 
prostatectomy.  
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Figure 4. Total number of radical prostatectomies as primary treatment per year of 
diagnosis in Sweden between 1998 and 2013. Information for year 2007 is not available.  
Graphical illustration: A Wallerstedt. Data adapted from NPCR. 
 
Potential advantages of radical prostatectomy over radiotherapy are that treatment failure is 
more easily identified and that it provides more accurate tumour staging by pathological 
examination of the surgical specimen. In addition lymph-node dissection can be performed 
which is the most accurate and reliable nodal staging procedure as available imaging 
techniques currently still have rather low sensitivity.51,61,62 When compared to watchful 
waiting, prostatectomy significantly reduced local progression, distant metastases and 
improved cancer-specific and overall survival rates in the Scandinavian randomized trial, 
SPCG-4.63 Radical prostatectomy is described more in detail in chapter 2.2. 
2.1.3.2 Radiotherapy 
External beam radiotherapy uses beams of gamma radiation, usually photons, directed at the 
prostate and the surrounding tissues to treat prostate cancer. Radiotherapy has been evolving 
and today it is possible to give radiation with higher precision enabling higher doses to be 
delivered with stronger effect but also lower risk for side-effects.64,65 Three different 
randomized trials have shown that radiotherapy in combination with endocrine treatment 
decreases mortality in locally advanced prostate cancer.66,67,68 Today there exists no 
randomized controlled trials that compares radiotherapy with radical prostatectomy. The 
studies that are available are difficult to draw any conclusions from because of possible 
selection bias and because the endpoints for determining treatment success or failure are 
different for radiotherapy and surgery.69 High risk prostate cancers have more than 15-20% 
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risk for lymph-node metastasis, and it may therefore be appropriate to treat with radiation.70 
However, there is no strong evidence that radiation therapy is effective against lymph-node 
metastasis. Standard treatment for external beam radiation in Sweden is currently 78 Gy in 39 
fractions, which has shown to improve cancer control.71  
The side effects after radiation therapy are related to microvasculature damage of the tissue in 
the bladder, rectum, striated sphincter and urethra. Short-term side effects are irritative 
urinary symptoms, flatulence, loose stools and mucus or bleeding from the rectum. In a 
prospective study 9% of patients reported distress related to bowel function one year after 
radiotherapy or brachytherapy.72 Urinary symptoms can also be persistent.73 Approximately 
50% of patients develop erectile dysfunction a few years after radiation therapy.37 This is 
caused by injury to the vasculature of the cavernous nerves and to the corpora cavernosa.  
External beam radiation is often combined with long-term hormonal therapy in locally 
advanced prostate cancers and localized high-risk disease since studies have shown benefit in 
terms of overall survival.74 There are some relative contraindications for the use of external 
beam radiation as well as brachytherapy. Patients with severe obstructive urinary symptoms 
are not suitable because of the increased risk for acute urinary retention. Patients with prior 
TURP are unsuitable if the cavity in the prostate is too large because it leads to technical 
difficulties in administrating the radiation treatment. Inflammatory bowel disease is a relative 
contraindication due to the risk of worsening gastrointestinal symptoms.  
In brachytherapy radioactive sources are planted directly into the prostate gland. There are 
two sorts of brachytherapy, low dose-rate brachytherapy (also known as "seeds") and high 
dose-rate brachytherapy. Low dose-rate brachytherapy is suitable for low and intermediate-
risk prostate cancers with limited distribution of Gleason grade 4. The treatment is performed 
over 2-3 hours under general or spinal anaesthesia. Iodine seeds are deposited in the prostate 
using needles under trans urethral ultrasound guidance and fluoroscopy. The seeds consist of 
iodine-125 with a half-life of 60 days. The radiation dose is approximately 145 Gy, which is 
substantially higher than the dose used in external beam radiotherapy. Observational studies 
have shown that the effect is comparable with external beam radiation and radical 
prostatectomy in low and intermediate risk cancers.75,76,77 Side-effects after brachytherapy are 
mostly urinary symptoms especially in patients with coexisting prostatic hyperplasia.77 To 
avoid these problems it is important to choose patients who fulfil the following criteria: 
prostate volume < 50 cc, no urinary residual, International Prostate Symptom Score <8 and 
no median lobe. The risk of long-term side effects is thought to be lower in brachytherapy 
compared to external beam radiation and radical prostatectomy besides more frequent 
urination. Persistent urinary symptoms occur in approximately 10% and erectile dysfunction 
in 15 to 50% of patients depending on the erectile function prior to treatment.58 
External beam radiation and high dose-rate brachytherapy can be given in combination. 
There are currently no randomized trials investigating its effect however there are 
observational studies that show a good effect particularly on high-risk cancers.78,79 The 
treatment is initiated with 3-5 weeks of external beam radiation followed by high dose-rate 
  13 
brachytherapy which is performed with almost the same method as low dose-rate 
brachytherapy. The difference is that needle’s are implanted in the prostate only temporarily 
during 10-20 minutes while the treatment is performed. The radiation dose to the surrounding 
organs is less and thus decreases the risk of side-effects compared to external beam radiation. 
The side-effects among most patients receiving this mode of treatment are irritative urinary 
symptoms and rectal symptoms. Many develop erectile dysfunction a few years after 
treatment to a greater extent compared to those who had received brachytherapy as 
monotherapy.58  
2.1.3.3 Active surveillance  
At the time of diagnosis not all prostate cancers are suitable for curative treatment. There has 
been a substantial increase in the incidence of prostate cancer since the introduction of PSA 
and it has contributed to the detection of many low risk, clinically insignificant cancers. It has 
been shown in studies that most men who die within 10-15 years after a diagnosis of low or 
intermediate risk prostate cancer will die from causes other than from the cancer itself.80,81 
Some reports have shown overdiagnosis (cancers detected by screening that would never 
cause the patient disability or death) in as much as 50% or more in older men.53 In a 
randomized controlled trial radical prostatectomy did not significantly reduce all-cause or 
prostate cancer mortality compared with observation after 12 years of follow-up.82 
Furthermore, there is uncertainty as to whether Gleason grade 3 has the ability to 
metastasize, and if this is so, the question remains whether such cancers should be treated at 
all.83 Some argue that it should not.84 However there is a correlation between the 
propagation of Gleason grade 3 and the risk for simultaneous Gleason grade 4 cancer.85 
Considering all the evidence, there is a place for active surveillance in selected cases of 
prostate cancer.  
 
In Sweden active surveillance is recommended for patients with very low risk prostate 
cancer and an expected survival of 10 years or more.58 This is to avoid overtreatment, as 
well as the potential side effects the treatment causes. The longer expected survival of the 
patient, the more important it is to perform a thorough investigation to exclude the 
possibility of a more aggressive cancer before committing a patient to active surveillance, 
since about 30 percent of all Gleason 3+3 in biopsies are upgraded to a higher Gleason grade 
after surgery due to sampling error.43 Based on this, about one third of all patients are 
understaged on their initial prostate biopsy, one biopsy alone is not sufficient to offer the 
patient active surveillance as an alternative.86 Therefore a re-biopsy has to be performed 
before commencing active surveillance. Active surveillance should not be mistaken for 
watchful waiting, which is the monitoring of a patient until he develops metastatic disease 
that requires palliative treatment.  
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Active surveillance according to Swedish National Guidelines consists of: 
 
• a new biopsy with 10 cores within 2-6 months after the initial biopsy, preferably in 
the anterior part of the prostate87 
• PSA repeated every 3-4 month 
• DRE repeated every 6-8 months for 2 years 
• PSA and DRE repeated every 6 months after the initial 2 years of active 
surveillance 
• re-biopsy every 2-3 years including 10 cores 
• optional re-evaluation of the primary pathology report 
• optional multi-parametric MRI 
 
The longer the expected survival of the patient, the lower the threshold for recommending 
treatment if monitoring shows any signs of more aggressive cancer. Active surveillance is 
not optimal for a patient with anterior cancer, a large prostate, a PSA ratio <0.1, 
prostatitis/UTI or family history of prostate cancer.58 Active surveillance can induce patient 
anxiety, as it causes the patient to live with an untreated cancer. This in it self may be a 
reason to initiate treatment.88,89 A potential downside of recommending active surveillance 
to men with low-risk cancers that are still curable is that such cancers could progress over 
time where potentially the opportunity for curative treatment could be missed. Furthermore 
multiple biopsies could complicate future attempts at nerve-sparing surgery through 
potential distortion of the anatomy. A randomized clinical trial, the SPCG-4 study, showed 
that patients treated with watchful waiting had shorter cancer-specific and overall survival 
compared to patients operated with radical prostatectomy.90 However, average self-assessed 
quality of life was similar between the two groups after 12 years of follow-up.91 
 
Active surveillance should be stopped when the patient is no longer a candidate for curative 
treatment and then the patient should be converted to watchful waiting for possible future 
hormonal treatment.  
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2.2 RADICAL PROSTATECTOMY 
2.2.1 Historical background 
The history of radical prostatectomy takes its beginning back in 1866 when Kuchler first 
described the perineal approach to remove prostate cancer.59 Kuchler only performed the 
operation on cadavers but the year after the famous surgeon Theodor Billroth was the first 
one to perform the operation on a patient to treat urinary obstruction at the University of 
Zurich and later described this in a medical journal.92 However, the outcome of the operation 
was poor as the patient died from complications. Later, in 1904 Professor Hugh Hampton 
Young performed a radical perineal prostatectomy in Johns Hopkins Hospital and he 
published data from his first operations in 1905.93 However, the peri- and postoperative 
morbidity was still very high. In 1945 Terence Millin was the first to describe the radical 
retropubic prostatectomy.94 The indication was initially treatment for prostatic obstruction. 
Patients were only mobilised four days after surgery and discharged 14 days postoperatively. 
Still the operation was associated with high mortality and complications such as substantial 
blood loss, severe urinary incontinence, erectile dysfunction and stricture of the 
vesicourethral anastomosis. The diagnosis of prostate cancer during this period of time was 
often reached through digital rectal examination finding a palpable prostatic nodule. At this 
stage the cancer had frequently already spread beyond the prostate and was not curable by 
prostatectomy. The discovery of prostate-specific antigen (PSA) in 1970 by Ablin et al. was 
revolutionary and led to a stage migration of prostate cancer towards smaller, potentially 
curable tumours and thus the demand for curative treatment options increased.95 During this 
period of time efforts were initiated to decrease the peri- and postoperative complications. 
Reiner and Walsh described the anatomy of the dorsal venous complex in 1979 and a few 
years later Walsh and Donker improved understanding of the periprostatic anatomy, 
especially the existence and function of the neurovascular bundles.96,97 They developed the 
anatomic radical retropubic prostatectomy which allowed the dissection to be performed with 
good visualization and preservation of cavernosal nerves and the external sphincter muscle, 
leading to lower rates of postoperative erectile dysfunction and incontinence. Walsh 
described the first prostatectomy with nerve-sparing technique in 1983.98 Other significant 
updates in the surgical technique was the knowledge of the anatomy of the puboprostatic 
ligaments99, urinary sphincter, prostate shape100 and the posterior rhabdosphincter101. The 
development of the surgical technique had started and it is still today continually enhanced to 
decrease postoperative morbidity.  
2.2.2 Anatomy of the prostate 
A detailed knowledge of the anatomy of the prostate and the surrounding tissues is mandatory 
when performing a radical prostatectomy to ensure reliable oncological and functional 
outcomes. Patrick Walsh once said: "You only see what you are looking for and you only 
look for what you know". Thus, it is of great importance to have precise knowledge of all 
relevant anatomical structures to facilitate surgical orientation and dissection during radical 
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prostatectomy since the surgical anatomy of the prostate and adjacent tissues is very 
complex.  
The prostate is a walnut-sized gland in men that is located between the bladder and the penis 
with the urethra running through the gland. The size of the gland increases with age. The 
prostate is divided into five zones: three glandular (the peripheral zone, the transitional zone 
and the central zone) and two non-glandular (the peri-urethral zone and the fibromuscular 
stroma). The peripheral zone constitutes almost 75% of the normal prostate gland and 
occupies the distal prostate gland, the area around the urethra distal to the seminal colliculus 
(an elevation in the wall of the urethra where the seminal ducts enter). This zone is were most 
cancers are located in the prostate. The transitional zone lies superior to the seminal 
colliculus, lateral to the proximal urethra, and posterior to the fibromuscular stroma. Benign 
prostate hyperplasia (BPH) is caused by enlargement of the transitional zone, compressing 
the peripheral zone or displacing it laterally. The central zone lies posterior to the urethra and 
superior to the seminal colliculus. The peri-urethral zone is a midline structure of cylindrical, 
internal smooth muscle sphincter that runs from the base of the seminal colliculus to the back 
of the bladder neck. This is the site of origin of the large median lobe of BPH. The anterior 
fibromuscular stroma forms the anterior surface of the gland. In close proximity behind the 
prostate lies the rectum. The prostate can therefore be examined via the rectum by a digital 
rectal exam or by transrectal ultrasound.  
The function of the prostate is to produce the majority (95%) of the seminal fluid, together 
with the seminal vesicles and the bulbourethral glands. The secretions produced by the 
prostate nourishes and protects the sperm produced in the testicles. There are two seminal 
vesicles located posterior-laterally to the prostate where the fluid from the prostate is 
collected. During ejaculation the seminal fluid is squeezed into the urethra from the seminal 
vesicles, the prostate and the spermatic duct.  
The prostate is covered with three fascial layers: Denonvilliers' fascia, the prostatic fascia 
and the levator fascia. Denonvilliers' fascia is located between the anterior walls of the 
rectum and prostate whilst the prostatic fascia is located anteriorly and antero-laterally in 
direct continuity with the capsule of the prostate. Laterally the prostatic fascia fuses with 
the levator fascia, which covers the pelvic musculature, to form the lateral pelvic fascia. 
The puboprostatic ligaments are paired fibrous bands originating from the visceral 
endopelvic fascia and their function is to stabilize the prostate, urethra and bladder to the 
pubic bone. They are considered an important part of the suspensory system of the 
continence mechanism.102 The dorsal venous complex or the Santorini's plexus covers the 
prostate ventrally and drains blood from the penile veins.103 The prostate is surrounded by a 
capsule-like structure, however it is not a well-defined capsule in an anatomic sense but 
rather a layer of fibro muscular fascicles, primarily smooth muscle.104  
 
The inferior hypogastric plexus or pelvic plexus innervates the mechanism of erection, 
ejaculation and urinary continence and contains sympathetic fibres that derive from the 
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hypogastric nerves originating mainly from T11-L2.105 The plexus also contains 
parasympathetic fibres primarily from the pelvis and sacral splanchnic nerves and originate 
from the ventral rami of S2-4. The nerves are located in two neurovascular bundles that are 
located on the lateral and anterolateral surface of the prostate.97,106,107 The bundles are not a 
distinct structure but consist of multiple finely dispersed fibres.108 The fascial and neural 
anatomy of the prostate are of special interest when performing a radical prostatectomy 
with nerve sparing surgery to improve functional outcome.109 The dissection can be 
performed in three different planes: intrafascial, interfascial and extrafascial (Figure 6). In 
the first case all the nerves are intended to be spared and in the third case the largest amount 
of tissue around the prostate is excised. Extrafascial dissection is the most safe approach for 
ensuring good oncological outcomes but carries with it a high probability of erectile 
dysfunction. The external urethral sphincter is located distal to the prostate apex and is 
innervated by autonomic branches from the pelvic plexus. The sphincter consists of two 
different muscle types. The outer muscle layer consists of striated muscle fibres and has 
been described as having a horseshoe appearance, often called the rhabdosphincter.110 The 
inner muscle layer surrounds the urethra completely and consists of smooth muscle and 
elastic tissue.111 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Schematic drawing of different dissection techniques for preservation of the 
neurovascular bundles. The left neurovascular bundle is preserved with an intrafascial 
technique (red arrow). The right neurovascular bundle is dissected in an interfascial plane 
(white arrow). Also demonstrated is the extrafascial dissection of the right neurovascular 
bundle (black arrow).112 
 
Lymphadenectomy in radical prostatectomy can be performed in two ways: limited or 
extended. In the limited version nodes in the obturator fossa located cranial and caudal to 
the obturator nerves are removed where as in the extended version the nodes overlying the 
external iliac artery, vein and nodes medial and lateral to the internal iliac artery are also 
Dorsal venous 
complex 
Denonvilliers' 
fascia 
Neurovascular 
bundle 
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excised.  
2.2.3 Different types of radical prostatectomy 
Radical prostatectomy is today performed in three different ways in Sweden: open retropubic, 
laparoscopic and robot-assisted radical prostatectomy. There is also a fourth approach: the 
radical perineal prostatectomy, which is not performed in Sweden today. A disadvantage with 
this technique is that the lymph-nodes cannot be removed through this approach. 
Furthermore, studies have shown that the technique is associated with higher incidence of 
rectal injuries.113 
2.2.3.1 Retropubic radical prostatectomy 
Retropubic radical prostatectomy was previously the most commonly used technique for 
many decades. It provides wide exposure of the operative field and direct access for pelvic 
lymphadenectomy and prostate excision with possibility of preservation of the neurovascular 
bundles. When performing a radical retropubic prostatectomy a midline incision is made 
from the symphysis pubis up toward the umbilicus. Careful suturing of the dorsal venous 
complex is made with suture-ligatures both distally above the apex of the prostate and 
proximally below the bladder neck. The apex dissection aims to free the urethral sphincter 
and the neurovascular bundles from the prostate without damaging them. It is important to 
visualize the transition between the urethra and the prostate as the risk of a positive margin is 
greatest in this area. The nerve-sparing dissection is then continued to free the neurovascular 
bundles dorsolaterally from the prostate. Diathermy should preferably not be used due to the 
risk of irreversible damage to the autonomic nerves.114 If extraprostatic growth of the tumour 
is suspected the resection is made wider, thus not sparing the nerves. The dissection of the 
bladder neck is made either with a wide dissection in case of an advanced cancer or 
alternatively with bladder neck sparing technique. Then the anastomosis between the bladder 
neck and the distal urethra is performed with 4 to 6 single sutures.  
2.2.3.2 Laparoscopic radical prostatectomy 
The laparoscopic approach was introduced to improve visualization of anatomy and with the 
belief that it would be associated with less bleeding, less postoperative pain and shorter 
convalescence compared to open surgery.115 However, this operative technique proved to be 
difficult with a long learning curve. Although perioperative bleeding is less, this technique 
has been debated to be associated with more postoperative complications such as ureteral 
injuries and anastomotic strictures.116,117  
Laparoscopic prostatectomy is performed with five laparoscopic ports that are surgically 
inserted through the abdominal wall and subsequently the abdominal cavity is inflated with 
carbon dioxide to form a pneumoperitoneum. Pneumoperitoneum is usually referred to as the 
cause for less bleeding in laparoscopic operations compared to open operations. Usually, a 
posterior dissection from the Pouch of Douglas is performed to dissect the vas deferens and 
the seminal vesicles. The urinary bladder is then taken down from the abdominal wall and the 
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space of Retzius is developed. The dorsal venous complex is then sutured with ligatures 
whereafter the prostate is freed from the bladder neck. Then the dissection of the 
neurovascular bundles is performed. If the cancer is poorly differentiated, is locally advanced 
or if the patient is preoperatively impotent, nerve sparing surgery is normally not performed 
to avoid the risk of a positive margin. Then the urethra is freed from the apex of the prostate. 
It is important not to make a too wide excision of the prostate so as not to damage the 
external sphincter as this might cause postoperative incontinence. However, the risk for 
positive margins is highest at the apex of the prostate so the dissection can not be too close 
either. Lastly the anastomosis between the bladder neck and urethra is made by 10-14 
continuous sutures. The prostate is removed from the abdomen in an endobag through an 
incision at the umbilical port.  
2.2.3.3 Robot-assisted radical prostatectomy 
Robotics in the practice of surgery started to evolve in the late 20th century. The first surgical 
application of a robot was in neurosurgery to orientate a needle for a brain biopsy under 
computerized tomography (CT) guidance.118 However the original prototype for the robot we 
use today for radical prostatectomy was created for military purposes to mount onto an 
armoured vehicle.119 Intuitive Surgical Inc. acquired the prototype from the military and gave 
birth to the da Vinci® robotic system. The system is based on the concept of immersive 
telepresence, which means that the surgeon operates on the patient remotely but still feels that 
he is in the operating room.  
In 2000, the first robot-assisted radical prostatectomy was performed in the world.120 The 
operative technique is the same as in traditional laparoscopic prostatectomy except that the 
surgeon controls the camera and two or three operating arms from the controls of a robotic 
console. Robotic technology was thought to provide better results due to improved 
visualization through better lighting, improvement of magnification and a three-dimensional 
image of the abdomen. Robotic instruments have also increased mobility with 7 degrees of 
freedom and more precise motor control in comparison with the conventional laparoscopic 
instruments that enables a more accurate dissection technique. Another advantage with the 
robotic technique is the improved ergonomics for the surgeon as compared to both the open 
and laparoscopic technique. The technology makes it easier to visualize the urethra and to 
sew an anatomically correct anastomosis without damaging the outer micturition sphincter, 
which is believed to result in reduced postoperative incontinence. The neurovascular bundles 
innervate the penis are attached to the prostate capsule and should be preserved to maintain 
potency after surgery. The robotic approach’s good visualization and extended mobility is 
thought to allow preservation of the nerves in a better way than with open surgery and thus 
lead to lower levels of impotence. In recent studies it has also been shown that preservation of 
the nerves is associated with lower rates of incontinence one year after radical 
prostatectomy.121,122 This evidence could widen the indication for nerve sparing surgery not 
only for preservation of potency but also preservation of continence.  
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The robotic technique has been proven to cause less perioperative bleeding, less transfusions 
and shorter hospital stay compared to open surgery.123 However the total cost is higher. With 
respect to long-term functional and oncological outcomes most studies have shown no 
difference between the techniques.124,125 However, in a meta-analysis Ficarra et al. showed a 
statistically significant advantage in favour for the robotic technique concerning 12 months 
urinary continence recovery and potency rates.126,127 A more important factor for the 
functional and oncological results is the individual skill and experience of the 
surgeon.128,129,130  Thus, it is of great importance that radical prostatectomy is performed by a 
select number of surgeons with a high annual volume of cases to be able to improve and 
maintain their surgical skills. A further potential advantage is that the robot-assisted 
technique seems to have a shorter learning curve when compared to laparoscopic and open 
surgery.131,132,133  
Today, there are no high-quality published studies in which open radical prostatectomy and 
robot-assisted radical prostatectomy are compared. Despite this, many surgeons adopted the 
robotic-assisted technology and it became more widely used, based on promising preliminary 
reports both in terms of postoperative morbidity and oncological results.134,135 Today the 
robotic technique is the most commonly used technique for radical prostatectomy in Sweden, 
about 65% of all prostatectomies in Sweden in 2013 were performed robotically (Figure 5).24 
In the US the numbers are even higher with 85% of all prostatectomies in 2011. Given the 
increased use of robotics there is a great need for evidence-based data proving that the robotic 
technique is at least as good or a better method than the conventional open technique.  
0 
200 
400 
600 
800 
1000 
1200 
1400 
1600 
20
09
 
20
10
 
20
11
 
20
12
 
20
13
 
N
um
be
r o
f c
as
es
 
Retropubic Laparoscopic Robot-assisted 
 
Figure 5. Type of radical prostatectomy as primary treatment in Sweden between 2009 and 
2013.  
Graphical illustration: A Wallerstedt. Data adapted from NPCR. 
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2.2.4 Complications 
Surgical technique should be as atraumatic as possible to reduce the risk of complications 
from surgery. Over the years the surgical technique has improved with increasing experience 
and the risk of side effects are decreasing. However, there is still a significant risk of 
complications after prostate cancer surgery. The two most common long-term side effects are 
urinary incontinence and erectile dysfunction that also have a significant impact on quality of 
life.136  
2.2.4.1 Short-term complications 
Short-term complications within 30 days of surgery was assessed in a meta analysis by 
Tewari et al in 2012 with data obtained from 400 articles representing 286,876 patients who 
had undergone radical prostatectomy, either open, laparoscopic or robot-assisted. Patients 
operated by robot-assisted prostatectomy had significantly lower PSA preoperatively and a 
lower percentage of men with pT3 disease compared to men operated by open or 
laparoscopic surgery.137 Bleeding is the most common complication of radical prostatectomy. 
In the meta analysis the robotic approach had significantly less bleeding and transfusion rates 
compared to both open and laparoscopic surgery (RARP 188 ml; 1.8%, ORP 745 ml; 16.5%, 
LRP 378 ml; 4.7%).137 There is substantial evidence that laparoscopic techniques cause less 
bleeding which is usually explained by the formation of a pneumoperitoneum during 
surgery.138,139  Hospital stay was also significantly shorter in men operated by robotic 
technique (RARP 4.0 d, ORP 9.9 d, LRP 6.3). Rates of mortality were very low and no 
differences were noted between the groups (RARP 0.04%, ORP 0.1%, LRP 0.04%).137 
Studies have shown that the most common cause of death within 30 days of the operation is 
acute myocardial infarction.140 Overall there was lower morbidity for robotic patients in the 
meta analysis with lower readmission, reoperation and total perioperative complication rates. 
The perioperative injuries that occurred with the robotic technique were nerve injuries 
(0.4%), ureteral injuries (0.1%), ileus (0.8%), rectal injuries (0.3%) and bowel injury 
(0.09%). Anastomotic leakage occurred in 3.5% in the same group. Wound infection (2.8% 
vs. 0.7%), hematomas (1.6% vs. 0.7%) and lymphoceles (3.2% vs. 0.8%) were significantly 
more common with the open technique compared to the robotic technique.137 The results 
from this meta analysis must be interpreted with care since the differences in patient 
characteristics described might explain differences in outcomes between the surgical 
techniques. However, in the absence of a randomized controlled trial this meta analysis 
provides a high level of evidence that the robot-assisted technique is at least comparable to 
the open technique.  
Thromboembolic events are also a known complication of radical prostatectomy. However 
the rates for deep venous thrombosis were lower for the robotic patients compared to open 
technique in the meta analysis (0.3% vs. 1.0%).137 Lymph-node dissection during radical 
prostatectomy increases the risk for thromboembolic events, especially in patients with 
previous thromboembolic diseases.141 The causes for the increased risk during lymph-node 
dissection could be due to potential intimal injuries, hematomas or postoperative 
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lymphoceles.142  In the open surgery thromboembolic events could be due to the extra 
peritoneal approach.143,144,145 Lymph-node dissection also leads to an increased risk of 
lymphocele formation, especially after open surgery.146  
2.2.4.2 Long-term complications 
Urinary incontinence 
Urinary incontinence after radical prostatectomy is a significant long-term complication that 
affects quality of life.147 Incontinence rates vary a lot in the existing literature, in a review 
using the definition of continence as no pad, incontinence rates ranged from 4% to 31% with 
a mean value of 16%.126 The large variation in incontinence depends on many different 
factors. Studies have shown that predictors of urinary incontinence in patients who underwent 
robot-assisted radical prostatectomy are patient age148,149,150,151,152,153, severe lower urinary 
tract symptoms (LUTS)151,154, comorbidities150 and preoperative erectile dysfunction149. Other 
factors that have been discussed as predictors are prostate volume155, obesity156,157,158 and 
surgeon experience159,160.  
Different surgical aspects have been discussed to improve the recovery of urinary continence. 
In a study by Freire et al. bladder neck preservation was associated with improved continence 
rates at 4 months after surgery compared to bladder neck resection and reconstruction, 
however no difference was seen at one or two years of follow-up.161 Also selective dorsal 
venous complex division162, nerve-sparing technique121,122 and posterior musculofascial 
reconstruction163,164 as well as anterior restoration of the pelvic space99,165 have been 
discussed as potential surgical aspects to reduce the risk of urinary incontinence after robot-
assisted radical prostatectomy. Comparing surgical techniques, a cumulative analysis of five 
studies in a review by Ficarra et al. showed a statistically significant advantage in favour of 
robotic surgery compared to both open and laparoscopic surgery in terms of 12 months 
urinary continence recovery.126 The absolute risk reduction was 3.8%.    
Erectile dysfunction 
The most common long-term complication after radical prostatectomy is erectile dysfunction. 
In a review of the literature the mean values of potency recovery was 70% at 12 months and 
79% at 24 months after surgery.127 However, erectile dysfunction is only a part of the 
impaired sexual health that affects many men after radical prostatectomy. There is also a 
significant loss in orgasmic function in many men which can consist of absence of orgasm 
(anorgasmia),  painful orgasm (dysorgasmia)166 and urine loss occurring during orgasm 
(climacturia)167. One cause that has been reported for dysorgasmia is bilateral sparing the tips 
of the seminal vesicles.168 Sparing the tips of the seminal vesicles during nerve-sparing 
radical prostatectomy has been believed to cause less damage to the pelvic nerves as they are 
located about 3-10 mm from the nerves.169 Impairment of the orgasmic function has been 
related to reduction in physical and emotional satisfaction which in turn may lead to sexually 
avoidant behaviour and disharmony in a relationship.170 
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The erectile dysfunction after radical prostatectomy is caused by damage of the autonomic 
nerves supplying the cavernosus which mediates the erection. With improving surgical 
technique it is today possible to preserve the neurovascular bundles which cover the surface 
of the prostate.98 The extension of nerve-sparing has an impact on potency rates.171 In a 
systematic review from Ficarra et al. bilateral preservation of the nerves was associated with 
a lower risk of erectile dysfunction after robot-assisted radical prostatectomy.127 Intrafascial 
technique has also shown a significant improvement in potency rates.172 Another aspect of the 
surgical technique in nerve-sparing is the level of the incision of the levator ani fascia that has 
been debated to play a role in the recovery of potency.173  
The risk for erectile dysfunction is thought to depend on several other factors such as 
comorbidities174 and preoperative potency status149,171. It has been shown that many men (30-
70%) are already impotent before their surgery and that the rates increases with age.175,176 
Age in itself is also predictor for postoperative erectile dysfunction.149,174 Conflicting results 
have been presented concerning the effect of obesity on potency outcomes.129,177,178 The 
experience of the surgeon has been discussed as a predictor for potency outcomes, however 
in a study by Zorn et al. no difference could be seen between inexperienced and experienced 
surgeons.160  
One can observe a large heterogeneity for the definition of potency which also can be an 
explanation for the variation in potency rates between different cohorts. The most common 
definition is an erection sufficient for intercourse regardless of the use of phosphodiesterase 
type 5 inhibitors. Many also use the SHIM score (Sexual Health Inventory for Men) which is 
more objective and reproducible. However, the cut-off value for what is considered normal 
has no consensus. A standardized classification has been proposed with SHIM 17 as a cut-off 
value.179  
There are many surgical aspects apart from nerve-sparing that have been thought to influence 
the potency recovery after robot-assisted radical prostatectomy. A study comparing 
extraperitoneal to transperitoneal approach in robot-assisted radical prostatectomy where all 
patients were preoperatively potent and received bilateral nerve-sparing surgery, showed no 
differences after 12 months follow-up.180 Many studies have evaluated thermal compared to 
athermal dissection of the neurovascular bundles as the classic nerve-sparing technique 
described by Walsh et al. was based on the idea that thermal dissection was harmful to the 
cavernous nerves.97,181 Experiments on dogs supported this belief.114 A meta analysis showed 
significant advantages in terms of early potency recovery in favour of athermal dissection.127 
However, conflicting results have been reported concerning longer follow-up in comparative 
studies.182 These results should also be contrasted to those results of numerous robotic 
surgeons that have used monopolar and bipolar energy for the dissection of the nerves and 
have still had good results with respect to potency.149,174 Today with the existing evidence, no 
definitive conclusion can be drawn concerning the use of energy during dissection of the 
cavernous nerves. Another aspect that has been debated is traction of the cavernous nerves 
 24 
during nerve dissection that could lead to neuropraxia, however there is no strong evidence 
that it has any effect on potency outcomes.171  
In a review comparing operation techniques the cumulative analysis showed significant 
advantages in terms of 12 months potency recovery after robot-assisted technique compared 
to open technique.127 In contrast, Hu et al. reported significantly higher prevalence of erectile 
dysfunction after minimally invasive radical prostatectomy compared to open prostatectomy, 
however the results have been debated to be influenced by the learning curve for the 
minimally invasive technique.183  
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3 AIMS 
 
The aims of this thesis were: 
 
1. To evaluate the definition of postoperative urinary continence after radical prostatectomy 
using self reported urinary bother and urinary leakage. 
 
2. To identify patient and tumour related factors that could predict incontinence after 12 
months after radical prostatectomy. 
 
3. To report the frequency of certain pre-specified short-term results and adverse events after 
both robot-assisted radical prostatectomy and retropubic radical prostatectomy, and to 
investigate potential differences between the two procedures. 
 
4. To investigate the association of lymph-node dissection to postoperative morbidity and 
incidence of thromboembolic events, by comparing patients operated with retropubic radical 
prostatectomy or robot-assisted radical prostatectomy with or without lymph-node dissection. 
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4 MATERIAL AND METHODS 
4.1 KS COHORT 
A consecutive series of 1411 prostate cancer patients from Karolinska University Hospital 
underwent radical prostatectomy (open or robot-assisted) between January 2002 and 
December 2006. No exclusion criteria were set and only patients with follow-up longer than 
one year were included in the study. Data was collected prospectively on clinical stage, 
biopsy Gleason score, PSA and routine pathology reports provided data on prostate weight. 
Validated patient questionnaires assessed the functional outcomes postoperatively. The 
development of the questionnaires was based on previous experience from our cancer 
survivorship program and it was refined after in-depth interviews with patients who 
underwent radical prostatectomy.184 Face-to-face validation ensured that the questions and 
answering alternatives were understood correctly. Informed consent was obtained from each 
included patient.  
Urinary incontinence was evaluated with three different questions. The two first questions 
were included in one main questionnaire whereas the third question was included in a 
questionnaire that was sent out 12 months postoperatively to a subgroup of the cohort (541 of 
1,179 patients). The main questionnaire also contained a question about urinary bother, to be 
able to evaluate the effect of postoperative incontinence. The main consecutive series of 1411 
is referred to as cohort 1 while the subgroup of 541 men from cohort 1 is referred to as cohort 
2. The questionnaires were collected by a neutral third party. The study was approved by the 
ethics committee. 
 
Urinary leakage questions: 
1) During the past six months how often did you change your protective pad during a typical day? 
• Not applicable, I don’t use any protective pad 
• Less than 1 pad/day 
• About 1 pad/day 
• About 2-3 pads/day 
• About 4-5 pads/day 
• About 6 pads or more/day  
 
2) During the past six months how much urine did you leak in the daytime? 
• Not applicable, I don’t leak urine in the daytime 
• Little 
• Moderate 
• Much 
3) Do you have urinary leakage? 
• Never 
• Leakage when coughing, sneezing or using pad during physical activity 
• Pad used continuously but not always wet 
• Pad used continuously and had to be changed because they are wet 
• Continuous leakage and need to change pads continuously 
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Urinary bother question: 
1) During the past six months, if you have had urinary leakage daytime and you would have to live with it the rest of your life, how would you 
find that?   
• Not applicable – I don’t have any leakage 
• It wouldn’t bother me at all 
• It would bother me slightly 
• It would bother me moderate 
• It would bother me much 
4.2 LAPPRO 
LAPPRO (Laparoscopic Prostatectomy Robot Open) is a prospective, non-randomized, 
controlled trial with the aim to compare outcomes after retropubic radical prostatectomy to 
robot-assisted radical prostatectomy. Fourteen centres in Sweden included patients in the 
study, where seven centres performed the open approach and seven centres performed the 
robot-assisted approach, between September 1, 2008 and November 7, 2011. Geographical 
location decided what operation technique was to be used for the majority of the patients, not 
patient or surgeon preference. The primary endpoint for the LAPPRO study is urinary 
incontinence. The three studies included in this thesis with data from the LAPPRO study are 
sub studies to the main study which is not yet published. The study was approved by the 
Gothenburg regional ethical review board and the trial is registered in the Current Controlled 
Trials database (ISRCTN06393679). 
Patients completed validated questionnaires preoperatively and at 3, 12 and 24 months 
postoperatively. The questionnaires were validated face-to-face in a clinical setting by experts 
and prostate cancer patients for mutual understanding and contained questions concerning the 
primary and secondary endpoints together with possible confounders and effect modifiers. 
Patient-reported data was prospectively collected by a neutral third party. Health-care 
professionals completed validated clinical record forms (CRF) before, during and 1.5-3, 12 
and 24 months after surgery. The questionnaires and CRF:s were further tested in a pilot 
study (n=100) after which final revisions were made. A detailed description of the study 
design and procedure including the development of the CRF:s and questionnaires has 
previously been published.185 All data was manually entered into a secured electronic 
database. To ensure quality assurance of the collected data approximately 1% of the data was 
re-entered in the database and cross checked. The recruiting sites were regularly monitored 
by two research nurses.  
Inclusion criteria were tumour stage cT1, cT2 or cT3 (TNM Classification of Malignant 
Tumors)27, no clinical signs of metastatic disease, PSA <20 ng/ml, age < 75 years, no 
previous malignancy, fitness for prostatectomy, informed consent and ability to read and 
write Swedish.  
4.2.1 Predictors of urinary incontinence 
The population for this sub study was all patients included in the LAPPRO study during the 
first 17 months, a total of 1529 patients. They had undergone their prostatectomy between 
September 1, 2008 and January 31, 2010 with a follow-up of 12 months. The focus of this 
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analysis was to find potential confounders for the primary endpoint, urinary incontinence. In 
order not to interfere with the results of the primary endpoint of the LAPPRO study the 
cohort for this paper was not divided into operating techniques. In the present study the 
inclusion criteria were fitness for prostatectomy, signed informed consent and ability to read 
and write Swedish.  
The primary endpoint, urinary incontinence, was evaluated with the following question: 
"How often do you change pad, diaper or sanitary aid during a typical day (24 h)? with 
response alternatives "Not applicable, I don't use any protective pad; Less than once/day; 
About 2-3 times/day; About 4-5 times/day; About 6 times or more/day". Incontinence was 
defined as the change of one pad or more per day. This definition was predefined in the study 
protocol of LAPPRO.  
4.2.2 Short-term complications 
The patient-reported adverse events were measured three months postoperatively. To avoid 
including results from the learning curve only patients operated by a surgeon with experience 
from at least 100 operations as primary surgeon were included in the present study. 
To evaluate adverse events we asked at 3 months; "Have you sought medical care for any of 
the following disorders after surgery?" with 22 specified disorders as answering categories, 
followed by "Yes" and "No". We used the same question to calculate the probability of 
seeking health care by dichotomizing between "never" and "once or more". Readmission was 
evaluated with the following question at 3 months; "Have you been readmitted to the hospital 
after the surgery?" with answer categories "Yes" or "No". After the patient could specify in 
free writing the cause for readmission. These answers were then classified into groups in a 
blinded fashion.   
4.2.3 Complications after lymph-node dissection 
In this paper the inclusion criteria were the same as for the whole LAPPRO study. The time 
point for measuring the adverse events was three months postoperatively. Either limited or 
extended lymph-node dissection was preformed and extended was done in most patient with 
high risk disease according to the D'Amico tables.186 During limited dissection the obturator 
nodes were removed and during extended dissection also the nodes overlying the external 
iliac artery and vein, nodes in the obturator fossa located cranial and caudal to the obturator 
nerve and nodes medial and (at some centres) lateral to the internal iliac artery were removed. 
Postoperative care consisted of early ambulation on the evening of the operation, stockings 
and low molecular weight heparin. Heparin were administered in the dose of 5,000 U for 
either 5-7 days or 10 days or more depending on centre preference and the patients risk for 
thromboembolic events (previous thrombosis, obesity and smoking).    
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4.3 STATISTICAL ANALYSIS 
4.3.1 KS cohort 
To calculate the proportion of patients with moderate or much bother from urinary leakage a 
statistical analysis was done. Comparison between groups were done by calculating relative 
risk, defined as the ratio of proportions, and it was estimated according to the log binomial 
regression model, presented with the 95% confidence interval. Missing data on one or more 
questions under consideration were excluded from each respective calculation. SAS®, 
version 9.2 was used for all calculations. 
4.3.2 LAPPRO 
4.3.2.1 Predictors for urinary incontinence 
Relative risk was used as effect measure for the analysis of the association between the 
preoperative factors and postoperative urinary incontinence. The relative risk was defined as 
the ratio of proportions, estimated according to the log binomial regression model and 
presented with 95% confidence intervals. Bivariate regression analysis with age added was 
done to calculate the age-adjusted relative risk. The estimates for the exponential curve 
describing the increased probability of leakage with age were obtained in the log binomial 
model of age at surgery and urinary incontinence. In the same figure we also present a step 
function showing the proportion in each age group changing their pad at least once a day. The 
figure was created in the free software R. Individuals with missing data were excluded in 
each respective calculation. For the statistical analysis the data were first entered into EpiData 
3.1 and then exported to SAS 9.2 (SAS Institute Incorporated, Cary, NC, USA). 
4.3.2.2 Short-term complications 
For the main LAPPRO study a power calculation was done to detect a difference on the 
primary endpoint; urinary leakage at 12 months (significance level p = 0.05, 80% power, 
two-sided test). Concerning the short-term results, to reduce the risk of significant effects that 
arise by chance, all the outcomes were defined before the start of the study. However, no 
adjustment was made for multiple testing and can be seen as a limitation of the study.  
The results are presented unadjusted and after three different adjustments (A, B, and C). 
Adjustment A is the use of stringent confounders. Adjustment B refers to all factors in A with 
the addition of tumour-related factors that are confounders, but may also be mediating 
factors, since they can affect the surgery differently in the respective surgical groups. 
Adjustment C refers to A and B with the addition of lymph-node dissection, which should 
also be considered a confounder, but may also be a mediating factor due to differences in 
technique in the respective surgical groups. 
Fifty data sets were made and imputation was performed for variables considered possible 
confounders in the statistical freeware R utilizing Multiple Imputations by Chained Equations 
(MICE).187 Missing information on prostate weight was imputed by making a linear 
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regression model of postoperative prostate weight, predicted by preoperative prostate volume 
from men who had information on both variables. For each endpoint, possible confounders 
were selected from 20 probable risk factors by choosing the variables that was statistically 
significantly associated (p<0.20). Relative risks were calculated as the proportion of patients 
from the robot-assisted group divided by patients from the open group. Log binomial 
regression models provided 95% confidence intervals for the unadjusted relative risks. We 
also calculated odds ratios, modelled by logistic regression, with the adjusted ratios calculated 
as a pooled estimate from the 50 imputed datasets. The statistical analysis was performed 
using SAS 9.3 for Windows (SAS Institute Incorporated, Cary, NC, USA).  
4.3.2.3 Complications after lymph-node dissection 
Log linear regression was used to calculate relative risks. Successive formation of logistic 
regression models (forward selection with the inclusion criterion p <0.10) was used to 
identify those of the possible confounders that were most strongly associated with the 
outcome of DVT and/or PE. The identified predictors were used to adjust the association 
between operation technique with or without LND, and DVT and/or PE. To perform the 
statistical analysis data were entered in EpiData 3.1 and exported to SAS 9.2 (SAS Institute 
Incorporated, Cary, NC, USA).  
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5 RESULTS 
5.1 URINARY INCONTINENCE 
5.1.1 Bother from urinary incontinence  
5.1.1.1 Patient characteristics 
Questionnaires were received from 1,288 patients (91%), and 1,179 among them had a 
follow-up of one year or more. Open radical prostatectomy was done in 411 patients, 
including 6 patients in cohort 2 and robot-assisted radical prostatectomy was done in 768 
patients, including 535 patients in cohort 2. Median age at surgery was 63 (range 37-78) and 
median follow-up was 2.2 years (range 1-5), however in cohort 2 the median follow-up was 
1.7 (range 1-4). Concerning clinical characteristics median PSA was 6.9 (range 0.4-117) and 
clinical stage was T1 702 (60%), T2 422 (36%) and T3 55 (5%).  
5.1.1.2 Pad use and urinary leakage in correlation to urinary bother 
The results show that 775 (67%) out of 1,163 patients reported no pad use while 123 (11%) 
reported less than 1 pad and 143 (12%) reported 1 pad used per day. When evaluating urinary 
bother correlated to how many pads the patient used the results showed that patients who 
used security pads had a more than 5 times higher risk for moderate or much urinary bother 
compared to men using no pads (RR 5.2, CI 95% 3.5–7.7) (Table 3). With increasing number 
of pads we could see an increasing risk for urinary bother (Figure 7). The same trend was 
noted for all three of the urinary leakage questions.   
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Bother from urinary leakage 12 months after radical prostatectomy 
a) PADs N/A No Little Moderate Much
!6 0/12 0/12 1/12 3/12 8/12 15.4 (11.1-21.4)
4-5 0/25 1/25 2/25 7/25 15/25 14.8 (10.8-20.3)
2-3 0/85 3/85 18/85 25/85 39/85 12.7 (9.4-17.2)
1 2/143 13/143 51/143 39/143 38/143 9.1 (6.6-12.5)
<1 8/123 23/123 54/123 23/123 15/123 5.2 (3.5-7.7)
0 542/775 88/775 99/775 23/775 23/775 1.0 reference
b) Urinary leakage
Much 0/42 1/42 2/42 5/42 34/42 70.8 (33.8-148.6)
Moderate 0/80 1/80 12/80 25/80 42/80 63.9 (30.4-134.2)
Little 49/504 111/504 198/504 89/504 57/504 22.0 (10.5-46.7)
No leakage 499/534 15/534 13/534 2/534 5/534 1.0 reference
c) Urinary leakage
Continuous pad change 2/12 0/12 2/12 2/12 6/12 27.5 (10.6-71.3)
Wet pad 2/16 0/16 3/16 2/16 9/16 28.3 (11.2-71.6)
Safety pad 4/78 4/78 28/78 23/78 19/78 22.2 (9.1-54.0)
Pad at physical activity 79/214 43/214 60/214 19/214 13/214 6.1 (2.4-15.5)
Never urinary leakage 165/206 20/206 16/206 3/206 2/206 1.0 reference
For exact wording of the questions see material and methods
Urinary leakage question a) and b) survivors answered 2.2 years postoperatively (range 1-5)
Urinary leakage question c) survivors answered 1 year postoperatively
RR moderate/much bother (95% CI)
 
Table 3. Bother from urinary leakage 12 months after radical prostatectomy. 
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Figure 7. Bother from urinary leakage 12 months after radical prostatectomy measured with 
three different questions for urinary leakage. 
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5.1.1.3 Cross-tabulation 
To further evaluate the rate of urinary incontinence after radical prostatectomy we compared 
the answers for the urinary leakage questions using a cross-tabulation. The results show that 
there is a wide variety in how men report the use of pads despite the same answer for urinary 
leakage. Of 776 men reporting no pad use, 514 (66%) reported no leakage and 255 (33%) 
reported little urinary leakage. Men that reported little urinary leakage also reported very 
different answers on pad requirements, 255 (51%) used 0, 101 (20%) used fewer than 1 and 
104 (21%) used 1 pad per day (Table 4). 
Daily pad requirement
0 a < 1 b 1 2-3 4-5 !6 Not stated Total
Urinary leakage daytime past 6 months
No leakage 514 14 5 0 0 0 3 536
Little 255 101 104 37 3 3 3 506
Moderate 3 8 31 31 5 2 0 80
Much 0 0 1 17 17 7 0 42
Not stated 4 0 2 0 0 0 9 15
Total 776 123 143 85 25 12 15 1179
Urinary leakage
Never 201 2 1 3 0 0 3 210
Occational pad-use during physical activity 148 43 18 4 0 0 2 215
Safety pad 6 17 38 14 3 0 0 78
Wet pad 2 2 5 5 2 0 0 16
Continues leakage 2 0 4 3 1 2 0 12
Not stated 5 3 2 0 0 0 0 10
Total 364 67 68 29 6 2 5 541
a Not applicable, I don’t use any protective pad
b Less than 1 pad/day
Cross tabulation of urinary leakage and pad requirement
 
Table 4. Cross tabulation of urinary leakage and pad requirement.  
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5.1.2  Predictors of urinary incontinence 
5.1.2.1 Patient characteristics 
The response rate was 89% consisting of 1360 men with a follow-up of 12 months. Patient 
characteristics showed median age at surgery; 64 years (range 41 to 77), clinical stage; T1 
771 (58%), T2 490 (37%), T3 32 (2%) and median preoperative PSA of 6.4 (range 0.1 to 
99.0).  
5.1.2.2 Age and preoperative urinary leakage as predictors for postoperative urinary 
incontinence 
The results show that patient age at surgery and preoperative urinary leakage were 
significantly associated with 12-months postoperative incontinence. Comparing men in the 
oldest age group (70 to 80) with 38% incontinence at 12 months postoperatively to the 
youngest age group (40 to 54) with 13% incontinence, the relative risk for incontinence was 
3.0 (95% CI 1.8-5.0) (Table 5). The risk for incontinence increases with age in a non-linear 
way and can be described with an exponential function (Figure 8).    
Among men having urinary leakage before their prostate cancer diagnosis 40% (27/67) were 
incontinent 12 months postoperatively compared to 22% (258/1149) in the group without 
urinary leakage before their prostate cancer diagnosis resulting in an age-adjusted relative risk 
of 1.8 (95% CI 1.3-2.4) (Table 6). 
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Table 5. Effect of patient and tumour-related factors on urinary incontinence after radical 
prostatectomy 12 months postoperatively 
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5.1.2.3 Other factors 
Men previously operated on for inguinal hernia had a statistically significant increased age-
adjusted relative risk of 1.4 (95% CI 1.2-1.8) for incontinence 12 months postoperatively (p = 
0.0012). However, when doing a multivariable regression analysis and additionally adjusting 
for preoperative urinary leakage the relative risk was diminished, 1.0 (95% CI 0.8-1.4). 
Presence of kidney disease, depression and mental disorders also showed a significant 
increased age-adjusted relative risk for 12 months postoperative incontinence, however these 
groups were small (Table 6). We further evaluated 36 factors including BMI, previous TURP 
and factors concerning clinical data, comorbidity and previous surgery and found no 
statistically significant association to postoperative incontinence. 
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Table 6. Effect of comorbidities and previous surgery on urinary incontinence after radical 
prostatectomy 12 months postoperatively 
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Figure 8. Likelihood of 12 months postoperative urinary incontinence with increasing age at 
surgery 
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5.2 COMPLICATIONS AFTER RADICAL PROSTATECTOMY 
5.2.1 Short-term complications 
The LAPPRO study collected in total data from 4003 men. For this study 1378 men were 
excluded; 980 because their surgeon had preformed less than 100 operations and 398 for not 
meeting inclusion criteria’s and other causes, as stated in the flow chart (Figure 9). 
Questionnaires were received from 2506 (95%) men and of these 745 were operated by open 
surgery and 1761 by robot-assisted surgery.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Flow chart for the analysis of short-term results of the LAPPRO trial. Numbers 
may not total correctly, because the same individual may have fulfilled more than one 
exclusion criteria.  
!
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5.2.1.1 Patient characteristics 
Men operated by robot-assisted surgery had significantly higher level of education, higher 
ASA score, higher clinical tumour stage and total length of cancer in their prostate biopsy 
compared to men operated by open surgery. Nerve-sparing surgery was more frequently 
performed during robot-assisted surgery, also after adjustment for tumour characteristics. 
Concerning lymph-node dissection, limited lymph-node dissection was done significantly 
more during open procedures whereas extended lymph-node dissection was more common in 
the robotic group. There was no statistically significant difference between the groups 
concerning comorbidities. When evaluating predictors for patient-reported readmission to 
hospital in our data we found that the factors that significantly increased the risk for 
readmission were PSA level, lymph-node dissection, prostate weight, clinical tumour stage, 
tumour stage of prostatectomy specimen, Gleason score on pathology specimen and a history 
of mental disorder.  
5.2.1.2 Parameters during hospital stay 
Robot-assisted surgery was associated with significantly less perioperative bleeding (185 vs. 
683 ml, p < 0.001) and shorter hospital stay (3.3 vs. 4.1 days, p < 0.001) compared to open 
surgery. However, the operation time was significantly shorter with the open technique (103 
vs. 175 min, p < 0.001). Reoperation during initial hospital stay was significantly more 
frequent after open surgery (1.6 vs. 0.7 %) which gives an odds ratio of 0.31 (CI 95% 0.11-
0.90) when adjusting for tumour factors and lymph-node dissection. No patient died during 
hospital stay (Table 7). Three patients died within three months of surgery in the robot-
assisted group and no one in the open group which resulted in no statistically significant 
difference, p = 0.56.  
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Table 7. Comparison between open surgery and robot-assisted surgery concerning 
parameters during hospital stay a 
5.2.1.3 Patient-reported adverse events and readmissions three months after surgery 
Men operated with open technique were more likely to seek health care compared to men 
operated with robotic technique (p = 0.03) within three months after surgery. Specifically, it 
was significantly more common to seek health care for cardiovascular reasons in the open 
group after adjusting for non-tumour and tumour-specific confounders, OR 0.63 (CI 95% 
0.42-0.94). The two cardiovascular diseases that caused the difference were pulmonary 
embolism (0.8 vs. 0.3 %) and deep venous thrombosis (1.9 vs. 0.2 %). Psychological reasons 
for seeking health care was significantly more frequent in the open group, with OR 0.72 (CI 
95% 0.53-0.96) after adjusting for non-tumour and tumour specific confounders (Table 8). 
There was no statistically significant difference in readmission rates three months after 
surgery between the operating techniques (Table 9).  
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Table 8. Comparison between open and robot-assisted surgery concerning patient-reported 
adverse events three months after surgery a 
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Table 9. Comparison between open and robot-assisted surgery concerning patient-reported 
readmissions three months after surgery a 
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5.2.2 Complications after lymph-node dissection 
5.2.2.1 Patient characteristics 
Questionnaires were received from 3544 (96%) of the patients. Open radical prostatectomy 
and robot-assisted radical prostatectomy was performed in 863 (24%) respectively 2681 
(76%) of the cases. Lymph-node dissection was done in 547 patients (15%), 266 (49%) out of 
these were limited and 281 (51%) were extended. Extended LND was performed 
significantly more than limited LND in the robotic group compared to the open group (73% 
vs. 22%). Open patients had less aggressive tumours with higher proportions of cT1 and 
Gleason score 6 tumours.  
Positive lymph-nodes were found in 49 men (9.5%). Extended lymph-node dissection 
resulted in higher lymph-node yield and the robot-assisted technique had higher lymph-node 
yields in both limited and extended lymph-node dissection compared to the open technique 
(Table 10).  
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Table 10. Lymph-node dissection stratified characteristics 
5.2.2.2 Complications and readmissions within 90 days 
Men treated with LND reported more wound complications (pain, bleeding and infections), 
cardiovascular (DVT and PE) and psychological events (anxiety and depression) (Table 11). 
Concerning readmissions, lymph-node dissection was associated with more frequent 
readmissions related to infectious, cardiovascular and surgical complications. Lymph-node 
dissection was also associated with increased risk of reoperation (Table 12). 
5.2.2.3 Thromboembolic events  
In the cardiovascular group, lymph-node dissection was specifically associated with a highly 
increased risk for DVT and PE compared to men who did not undergo lymph-node 
dissection, age-adjusted RR 7.8 (95% CI 3.51-17.32) and 6.29 (95% CI 2.11-18.73) (Table 
11). When evaluating predictive factors for DVT and/or PE we found that a history of 
thrombosis, stage pT4 disease and Gleason score 8 or greater increased the risk while low 
alcohol consumption (once per week) on the other hand was protective. Open surgery overall 
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resulted in a statistically significantly higher risk for DVT and/or PE compared to robot-
assisted surgery, RR 3.46 (95% CI 1.74-6.89). When only looking at men who did not 
undergo lymph-node dissection and comparing the surgical techniques, we saw that open 
surgery was significantly associated with an increased risk for DVT and/or PE compared to 
robot-assisted surgery, RR 3.20 (95% CI 1.16-8.83) (Table 13).  
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Table 12. Patient reported 90-day readmission causes by system unadjusted and adjusted for 
age.  
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Table 13. DVT and PE by ORP vs. RARP with vs. without LND according to patient reported 
90-day adverse events unadjusted and adjusted for possible confounders. 
 
 48 
6 DISCUSSION 
This thesis has evaluated complications after surgery for prostate cancer. In the first two 
papers we investigate urinary bother and predictors for postoperative incontinence. We found 
that even small occasional amounts of urinary leakage can cause the patient much bother and 
that the use of no pads is not equivalent with no leakage. Considering this, if continence is 
defined by pad use (e.g. safety pad) then a certain number of men who experience much 
bother from urinary leakage will nevertheless be considered continent. Increased age at 
surgery and preoperative urinary leakage proved to be significant predictors for incontinence 
one year after surgery. In papers three and four we evaluated two different surgical 
techniques for treatment of prostate cancer concerning short-term complications within three 
months of the surgery. The results showed that men operated by robot-assisted surgery were 
less likely to be re-operated during initial hospital stay and less likely to seek health-care 
within three months of the surgery compared to men operated by open surgery. The open 
technique had shorter operating time but resulted in more perioperative bleeding and longer 
hospital stay compared to the robot-assisted technique. There was no statistically significant 
difference in readmission rates between the groups within 3 months after the operation. 
Lymph-node dissection during radical prostatectomy increased the incidence of deep venous 
thrombosis or pulmonary embolism sevenfold. Open surgery increased the risk threefold 
compared to robot-assisted surgery.  
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Validity  
Validity is the extent to which the endpoint of a study corresponds accurately to the real 
world. Validity can be divided into internal and external validity. Internal validity is an 
expression of how well a study measures what it is intended to measure. Internal validity is 
affected by systematic errors such as selection bias, information bias and confounding. 
External validity, or generalizability, indicates the degree to which one can generalize the 
results obtained to other populations or situations. To describe the validity of the results in 
this thesis this discussion will start with considering systematic errors that could arise in these 
studies. Overall, the studies in this thesis have high internal validity as the risk of systematic 
errors are relatively low due to the study designs and the methods used to overcome potential 
confounders. The results of the LAPPRO study has high external validity because data is 
derived from 14 different centres, thus is more representative of real life practice compared to 
a single specialised institution.  
6.1.2 Selection bias  
Selection bias is a systematic error that can occur in the recruitment of a study population. 
Selection bias cannot be corrected for in the analysis and therefore it can influence the 
internal validity. In our studies the risk for selection induced problems were lowered by 
including a consecutive series of men in both cohorts used. Non-participation can be a risk 
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for selection bias if such individuals have different characteristics compared to those who do 
participate. A strength of the two cohorts used in this thesis is the high participation rate 
which reduces the risk of selection bias. Another strength is that inclusion to each respective 
technique was decided upon geographical location rather than patient or surgeon preference. 
This is because the Swedish Health Care is organized by county, and patients are not free to 
seek health care across county borders by their own inclination. The risk for selection-
induced problems would be reduced by this fact since all patients will be treated with one 
method only based on where they live rather than the preference of the different surgeons.  
6.1.3 Information bias  
Information bias is a systematic error that occurs when the information is collected in 
different ways for the different groups that are intended to be compared. Data collection 
errors can occur for either the exposure or outcome. The term misclassification is often used 
for this concept. Recall bias, measurement bias and detection bias are different types of 
information bias. One type of information bias that could arise in the first and second article 
is pads status as the subjective method for measuring urinary incontinence. When the 
outcome is urinary bother one can imagine that the pads status question blurs the effect 
when the patients personality plays a role in the number of pads used. One patient could be 
very bothered and use many pads despite experiencing little urinary leakage, compared to 
another patient experiencing the same amount of leakage and yet is less bothered by these 
symptoms, thus using less protection. On the other hand, if the outcome is operation 
technique it would be more important to have a more objective method for measuring 
incontinence. However, making the evaluation more objective, for example, by using 
urodynamic assessment, would have been difficult in such a large cohort. Furthermore, pads 
status is currently widely recognized as a method for evaluating postoperative incontinence. 
Today more emphasis is placed on the patients’ experience, which is a further reason to 
evaluate incontinence by questionnaires answered by patients. Another potential source of 
information bias is that no discrimination was made between urge and stress incontinence. 
Urge incontinence is usually caused by overactive bladder is not typically incurred after 
prostate cancer surgery. Not to exclude these patients may have affected our outcomes. 
Incontinence was defined as the change of one pad or more per day in paper II. This 
definition is not as strict as what we propose in paper I after having evaluated urinary leakage 
and urinary bother. However, the definition was predefined from the study protocol for 
LAPPRO and the decision was taken through consensus among the research group based on 
the clinical practice at that time. This definition will also be used for the final analysis of the 
primary endpoint of LAPPRO.  
In paper III and IV there is a lack of a standardized tool for the assessment of the adverse 
events which could lead to information bias. However, at the time when the study was 
designed and initiated, the now widely used Clavien-Dindo system of systematic grading of 
adverse events after surgical procedures, was not generally recognized.188,189 The Clavien-
Dindo classification requires data on the management of the complications and this 
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information was unfortunately not included in the clinical report forms. Additionally, there 
was no standardized postoperative clinical pathway in the study which might have influenced 
the data on hospital stay. Furthermore, since health-care professionals were not blinded the 
reports could be influenced by their preference for the surgical technique used in their centre. 
The ‘‘I want to please my surgeon’’ attitude among patients however, is possibly not related 
to surgical technique and should largely be avoided when using questionnaires.190,191 
The risk for information bias in the present studies are minimized by the large populations 
evaluated and by using validated self-assessed patient-questionnaires where one question is 
used for one phenomenon, to strive for a clear and mutual understanding. The information 
has been obtained and collected in the same way for both surgical groups. Furthermore, 
questionnaires were collected by a neutral third party to prevent interviewer related problems.  
6.1.4 Confounding  
An effect-measure can erroneously be deviated by extraneous risk factors for the outcome we 
study, and this source of error is often cited as confounding. Confounding can either 
strengthen or weaken an association. If the prevalence of the confounding factors are 
different in the groups that are compared then the observed association can be 
misrepresented. To overcome the effect of confounders there are five different methods: 
randomization, restriction, matching, stratification and adjustment.  
Surgical experience and surgical technique are potential confounders when evaluating urinary 
incontinence after radical prostatectomy. However, these factors were not analysed as 
predictors for incontinence in paper II as only preoperative patient- and tumour-related 
factors for postoperative incontinence were evaluated. This might be seen as a limitation but 
the aim of the study was to identify potential confounding factors for the final analysis of 
LAPPRO with the primary endpoint of urinary incontinence 12 months after surgery. 
Although no distinction was made between high- and low-volume centres in the analysis, 
most of the operations were performed at high-volume centres. High- and low-volume 
centres could be confounders when evaluating surgical complications in paper III and IV. But 
one can also say that using all centres and not dividing them into groups could increase the 
generalizability of the study.  
In our studies we have been highly diligent at collecting data on all possible confounders in 
the validated questionnaires and from the clinical data. To overcome the possible effect of 
confounders in our papers we used adjustments. In paper III, of the possible confounders, 
those who were significant at the 20% level in log binomial regression analysis were assumed 
to be confounders and were adjusted for in each outcome respectively. Furthermore, data 
from paper III is presented with three different adjustments because tumour-related factors 
and lymph-node dissection can either be seen as confounders or as mediating factors due to 
differences in technique in the respective surgical groups. In paper IV statistical models with 
forward selection were used to identify those confounders that were most strongly associated 
with the outcome from a list of possible confounders. The identified predictors were used for 
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adjustment.  
6.2 LATEST EVIDENCE 
6.2.1 Bother from urinary incontinence 
Our data shows a highly increased risk for urinary bother even at small rates of urinary 
leakage. Of men reporting use of no pads 6% reported much or moderate bother compared to 
31% in the group wearing a safety pad. This results in a relative risk of 5.2 (95% CI 3.5-7.7). 
These 6% of men who were bothered despite using no pads could be explained by the fact 
that use of no pads is not equivalent to no leakage. Two recent studies confirm the highly 
increased risk for urinary bother after radical prostatectomy. The Prostate Cancer Outcomes 
Study (PCOS) reported that, in a cohort of 1655 men who had undergone radical 
prostatectomy had significantly more urinary incontinence and urinary bother compared to 
men undergoing radiotherapy at 2 and 5 years, however no significant differences were 
apparent 15 years after diagnosis.192 Two years after surgery 11% of the men who had 
undergone prostatectomy were bothered 'moderately' or 'much' from their urinary 
incontinence. Similarly results from the CaPSURE registry showed that men undergoing 
nerve sparing and non-nerve sparing radical prostatectomy reported 30 vs. 31% urinary 
bother two years after surgery.193 
6.2.2 Predictors of urinary incontinence 
Our data shows that with increased age there is a higher prevalence of incontinence one year 
after surgery which increases exponentially. There are a lot of studies investigating the 
predictors of incontinence after radical prostatectomy and several studies have found age to 
be an independent predictor for the return of urinary continence.150,158,194,195,196,197 However, 
others have found no association between the two.198,199,200 Nilsson et al. reported similar 
results that age at surgery predicted long-term urinary incontinence in an exponential manner 
with a 6% relative increase every year.148 In our study we also found preoperative urinary 
leakage to be an independent predictor of postoperative incontinence at 12 months. In a 
national prospective study including 844 patients Holm et al. confirmed these results and 
found that preoperative urinary incontinence and sexual dysfunction were the strongest 
predictors for urinary incontinence 12 months after radical prostatectomy.201 In recent years 
there has been discussion as to whether nerve-sparing surgery has any effect on urinary 
incontinence beyond its benefit on potency. Kaye et al. published a prospective study with a 
cohort of 102 preoperatively potent men undergoing either laparoscopic or robot-assisted 
radical prostatectomy.122 Their results showed that completely sparing at least one 
neurovascular bundle along with its supportive tissue had a large beneficial effect on the 
recovery of urinary continence. Recent results from the LAPPRO study supports these 
results. The data showed a strong association between the degree of nerve sparing and urinary 
continence one year after surgery.121 However, a meta-analysis including 27 longitudinal 
cohort studies demonstrated an association between nerve-sparing and improved urinary 
continence only up to six months postoperatively.202  
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6.2.3 Robot-assisted radical prostatectomy vs. open radical prostatectomy 
The primary endpoint of the LAPPRO study which is urinary incontinence 12 months after 
surgery in men undergoing robot-assisted radical prostatectomy vs. men undergoing open 
radical prostatectomy, has not yet been published. The results are expected to be published in 
the beginning of 2015. A similar study was recently presented at the EMUC meeting 
(European Multidisciplinary Meeting on Urological Cancers) in November 2014 in Lisbon. 
Ong et al. presented a prospective study with data from the Victorian Prostate Cancer 
Registry (PCR) including 2333 men undergoing robot-assisted or open radical 
prostatectomy.203 Their results showed no significant differences at 12 months in urinary and 
sexual function, however the robotic patients had significantly better short-term oncological 
outcomes (PSM and BCR) compared to open patients. Contradicting theses results, in the 
annual report of the National Prostate Cancer Registry of Sweden 2013 data showed that 
men who had undergone radical prostatectomy and were potent prior to surgery had 
significantly less erectile dysfunction one year after robot-assisted surgery compared to 
those men operated by open surgery (66% vs 79%, p = 0.01).24 
6.2.4 Short-term complications 
The results from LAPPRO showed that men operated by robotic surgery were less likely to 
be re-operated during initial hospital stay and also less likely to seek health-care within 
three months after surgery compared to men operated by open surgery. The robot-assisted 
technique was also associated with less perioperative bleeding and shorter hospital stay 
compared to the open technique. A recent multi-institutional retrospective study comprising 
data from 5471 men undergoing either open (20.1%) or robot-assisted (79.9%) radical 
prostatectomy, showed that open surgery was associated with higher rates of overall 
complications (23.25% vs. 5.62%, p = <0.001), but not higher rates of reoperations (1.09% 
vs. 0.96%, p = 0.689) compared to robot-assisted surgery.204 Unlike the LAPPRO results, 
this study found a difference in readmission rates favouring the robotic technique (5.47% vs 
3.48%, p = 0.002). However, Gandaglia et al. found no significant differences concerning 
overall complications or readmission rates in 2439 men undergoing either open or robot-
assisted radical prostatectomy. Nevertheless, the robot-assisted technique was associated 
with a higher probability of experiencing 30- and 90-day genitourinary and miscellaneous 
complications but with lower risk for blood transfusions and prolonged length of hospital 
stay.205 
6.2.5 Complications after lymph-node dissection 
Results from the LAPPRO trial showed that lymph-node dissection during radical 
prostatectomy was associated with a sevenfold increased incidence of deep venous 
thrombosis or pulmonary embolism and that open surgery increased this risk more than 
robot-assisted surgery. A study by Van Hemelrijck et al. which assessed the risk of 
thromboembolic events in 45,065 patients undergoing different types of urological surgery, 
found that laparoscopic and open radical prostatectomy with lymph-node dissection was 
strongly associated with thromboembolic events (HR for pulmonary embolism 8.1 (95% CI 
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2.9-23.0) and 7.8 (95% CI 4.9-13)).141 There are several possible mechanisms that could 
explain the association between deep venous thrombosis and pulmonary embolism to 
lymph-node dissection. Lymphocele formation, which has been reported as the most 
frequent complication after lymph-node dissection (0-8%) could lead to significant pressure 
on the iliac veins as the retroperitoneal space is limited.206 The same effect could be caused 
by hematoma. Moreover, excessive bleeding which requires blood transfusion can cause 
hyper coagulation. Other factors that could play a role are malignancy, pelvic manipulation, 
patient age, operating time and comorbidities. In LAPPRO we found a history of 
thrombosis, pT4 stage cancers and Gleason scores of 8 or greater to be predictive factors 
for thromboembolic events.  
It is known that the larger the extension of the lymphadenectomy, the greater the chance of 
finding a positive node.60,206,207 Furthermore, the overall numbers of positive nodes 
increases along with the total number of nodes removed.208 However, the number of nodes 
removed is related more to the experience of the surgeon than the surgical technique.209 The 
latest review in the field showed that extended lymph-node dissection revealed positive 
lymph-nodes in up to a third of patients.210 With this evidence and consideration of the 
significant morbidity caused by lymph-node dissection, combined with the strive towards 
treating more advanced cancers surgically, there must be further deliberation by the surgeon 
when selecting patients for lymph-node dissection. It would be better to strategically 
remove lymph-nodes that are important rather than removing as many lymph-nodes as 
possible. One technique that is already in development is the sentinel node technique, 
which can be optimised with fluorescence guidance.211 The concept is to identify the 
lymph-nodes that are most likely to contain metastatic cells (sentinel node).  
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7 CONCLUSIONS 
Despite a great development in the surgical technique for prostate cancer in the recent 
decades, the surgery still leads to a significant risk of postoperative complications. Urinary 
incontinence is a long-term side effect that negatively impacts quality of life. The definition 
of continence is today often based on the number of pads the patient uses, however a 
standardized definition does not presently exist. In our data we saw a wide variation in pad 
use for the same amount of leakage as well as a high increased risk of urinary bother even at a 
small rate of urinary leakage. The use of no pads was not equivalent to total urinary 
continence. When considering this, pad status as a definition of continence is not without 
limitations.  
Our research has highlighted that there is need for a standardized definition of continence in 
the field of surgical treatment of prostate cancer. This would facilitate comparison between 
different surgical cohorts but also take the patient perspective into consideration. 
Furthermore, our research has shown that men with preoperative urinary leakage and those of 
older age at surgery are at higher risk of postoperative urinary leakage and that this must be 
taken into consideration prior to any treatment decision. 
When comparing the two surgical techniques of open and robot-assisted radical 
prostatectomy our large prospective study showed that despite a longer operating time, 
patients operated by robot-assisted surgery had significantly less bleeding and shorter hospital 
stay compared to patients operated by open surgery. Patient-reported data at three months 
showed that patients operated by the robot-assisted technique had a lower risk of re-operation 
during initial hospital stay and were less likely to seek health-care compared to patients 
operated by the open technique. Lymph-node dissection during radical prostatectomy 
increased the risk for thromboembolic events (deep venous thrombosis and pulmonary 
embolism), however the risk was significantly higher in men operated by open technique 
compared to the robot-assisted technique. Patients with previous thrombosis and high risk 
disease (pT4 stage and Gleason ≥8) especially had an increased risk for thromboembolic 
events. Since the morbidity from particularly pulmonary embolism is clinically significant, 
our findings highlight that these procedures may warrant prolonged prophylaxis and 
screening during and after surgery. In light of this there must be a strong indication for 
including this procedure during radical prostatectomy.  
In conclusion, we have found that there are certainly some significant short-term advantages 
of the robotic technique over the open prostatectomy. However, evaluating the pros and cons 
of robot-assisted radical prostatectomy as compared with open surgery involves further 
assessment of a large number of short- and long-term outcomes, including economic 
consequences and cure rates. These aspects will be addressed by the forthcoming results from 
the LAPPRO study. 
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8 FUTURE PERSPECTIVES 
In this thesis we can conclude that men undergoing radical prostatectomy due to localized 
prostate cancer have a significant risk of long-term urinary incontinence and that even small 
rates of incontinence may cause a lot of bother. The advantages of a multicentre study is that 
it provides data that is more likely to represent a generalizable incidence of incontinence 
rather than results from a single centre of excellence that could be influenced by a number of 
systematic errors. Furthermore we conclude that robot-assisted technique as compared to 
open technique has advantages on short-term outcomes such as lower risk for reoperation, 
thromboembolic events and the need to seek health-care after the operation.  
In the future, how can we reduce the risk of morbidity after surgery for prostate cancer? The 
best way to avoid complications would be not to operate at all. However, since we know that 
mortality is reduced by surgery in especially intermediate and high risk prostate cancers the 
most important issue to reduce the overall morbidity would be to select our patients better and 
only operate those with true benefit from the surgery. We know today that there is a 
substantial overtreatment, thus causing many men life-long side effects from treatment of 
asymptomatic prostate cancer that could have remained undiagnosed.212 The problem is that 
today we detect too many innocuous cancers. The latest update from the SPCG4 study 
showed that radical prostatectomy lowers the mortality primarily from intermediate-risk 
cancers, whereas patients with low-risk cancers had at most 10% risk of dying from prostate 
cancer without any treatment and the patients with high-grade disease usually developed 
metastasis despite surgery. Furthermore, young men had more to gain from surgery compared 
to older men.1 Thus, the future in prostate cancer diagnostics lies in detecting only the 
patients with intermediate and high risk cancers that would have the most benefit from the 
surgery. The 13 years follow-up of the ERSPC study, which is a multicentre randomized 
screening trial with PSA, concluded that the main weakness of screening is overdiagnosis and 
overtreatment although they showed significant reductions in prostate cancer mortality where 
781 must be screened or 27 prostate cancers detected to avert one death.213 However, the 
benefits of screening were even greater in the Swedish cohort from the Göteborg 
Randomized Population-based Prostate Cancer Screening Trial where only 139 needed to be 
screened or 13 prostate cancers detected to avert one death.36 Diagnostics could improve 
substantially through the use of MRI and today there are interesting on-going trials with the 
aim to investigate whether MRI in combination with PSA could improve the detection of 
more advanced cancers, leaving the low-risk cancers undetected. Another important part of 
improving diagnostics is the research into new biomarkers for prostate cancer with high 
specificity and sensitivity, especially for detection of high-grade cancers.54,214,215 
Furthermore, improved preoperative staging could increase the surgeons knowledge of the 
localization and distribution of the tumour when planning surgery to minimize the risk of 
postoperative morbidity. An example is preoperative MRI that provides the surgeon better 
knowledge of the localization of the tumour in order to spare as much as possible the nerves 
affecting both postoperative continence and potency. Another example of 'perioperative 
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staging' is the NeuroSAFE that enables frozen section of the prostate during surgery and thus 
lowers the risk for positive surgical margins and increases the extent of nerve sparing.216  
A second important issue of incontinence after radical prostatectomy is that the definition of 
incontinence varies across the world and thus makes data comparison between different 
cohorts complex. The future research of surgical technique in prostate cancer relies on an 
international consensus in defining continence and quantifying it. According to our results a 
suggestion for an international definition of continence could be pad and leak free to avoid 
including any patients with bother from urinary leakage being defined as continent. A desired 
future development would be to use a more objective method for evaluating postoperative 
incontinence, especially when comparing operation techniques with the outcome of 
incontinence to avoid information bias. An example would be to improve the technology to 
measure the actual leakage through simplified methods for weighing pads or with a urine 
sensor placed in the underwear similar to those used in enuresis alarms. However, when 
evaluating other outcomes such as patient bother from urinary leakage, then pads status could 
be used for measurement of urinary leakage and it would be of less importance to use a more 
objective method. Moreover, age and preoperative urinary leakage should always be 
considered when planning a patient for radical prostatectomy as our research has shown that 
they have an increased risk of postoperative incontinence.  
There is evidence to continue the implementation of robot-assisted surgery since our data 
showed that robotic surgery has several favourable outcomes short-term outcomes compared 
with open surgery and has not demonstrated any substantial adverse outcomes within three 
months. Given that lymph-node dissection is associated with an increased risk of deep venous 
thrombosis and pulmonary embolism these patients should in the future be treated with an 
extended treatment period of low molecular heparin, especially patients undergoing open 
surgery, those who have had a previous thrombosis and those with high-risk tumours with 
pT4 or GS ≥8. Patients who undergo lymph-node dissection should also be thoroughly 
informed of the risk of thromboembolic events in order for them to seek health-care at an 
early stage if symptoms occur. 
It is of importance to continue to evaluate and improve the surgical technique in the treatment 
of prostate cancer to further reduce the risk of postoperative complications both in the short 
and long-term. This can be done with future epidemiological studies in which the surgeon 
documents how the different steps of the surgery are performed and prospectively follow-up 
the short and long-term functional outcomes. To decrease the rate of postoperative 
incontinence it would be useful to continue evaluating the possible effect of posterior 
musculofascial reconstruction and anterior restoration of the pelvis as well as to further study 
whether the length of the urethra plays a role in urinary continence. Recent data from the 
LAPPRO study has shown that nerve-sparing also has a positive effect on postoperative 
continence.121 To gain a deeper understanding of this relationship future studies could focus 
on further mapping the anatomy of the nerves and to evaluate their impact on the function of 
the urethral sphincter and the micturition reflex.  
  57 
A radical prostatectomy is intended to be curative and we expect most patients to remain 
active and live many years after the procedure. Thus, reduced complication rates would 
improve quality of life and reduce suffering for many years for a significant number of 
patients. 
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9 SVENSK SAMMANFATTNING 
Prostatacancer är den vanligaste cancerrelaterade dödsorsaken hos män i Sverige idag. Varje 
år insjuknar ca 9000 män och ca 2400 av dessa avlider till följd av sjukdomen. På senare år 
har antalet diagnostiserade fall ökat markant, dels p.g.a. utökad och förbättrad diagnostik av 
tidig prostatacancer genom introduktionen av PSA samt dels p.g.a. en ökad livslängd hos 
befolkningen. Detta har lett till att fler män idag kan erbjudas kurativ behandling när man på 
ett tidigt stadium diagnostiserar cancern då den fortfarande är lokaliserad.  
Kurativt syftande behandling utgörs av strålbehandling alternativt radikal prostatektomi. En 
stor svensk randomiserad studie om radikal prostatektomi, SPCG-4 studien, har visat en 
signifikant skillnad i dödlighet i prostatacancer från 28,7 % i gruppen som följdes aktivt 
(”watchful waiting”) till 17,7 % i den opererade gruppen efter 18 år.1 Denna kunskap om att 
operation förbättrar överlevnaden har bidragit till att kirurgi har blivit den vanligaste 
behandlingsformen i Sverige. Antalet radikala prostatektomier har de senaste 10 åren ökat 
från ett hundratal till över två tusen per år. I SPCG-4 studien såg man att den absoluta 
effekten av radikal prostatektomi i prostatacancerspecifik dödlighet var relativt låg, siffrorna 
visade att man behöver operera 8 män för att en ska förhindras från förtidig död.1 Sannolikt är 
antalet ännu högre idag då vi nu använder PSA som screening och hittar patienter tidigare i 
sjukdomsförloppet samt att det i dagsläget inte finns någon säker diagnostik avseende vilka 
cancrar som progredierar till avancerad sjukdom. Detta är ett stort dilemma med lokaliserad 
prostatacancer att många patienter lever många år utan progress eller symtom från sin cancer 
och att de i många fall dör av andra orsaker.  
De vanligaste komplikationerna till radikal prostatektomi är inkontinens och erektil 
dysfunktion (impotens). En genomgång av litteraturen har visat att mellan 4-31% har 
bestående urinläckage 12 månader efter operationen, dock är risken för allvarlig inkontinens 
låg.126 Risken för erektil dysfunktion av någon grad är högre och har visat siffror mellan 10-
46% ett år efter operationen.127 Risken för överbehandling måste vägas mot komplikationerna 
som ingreppet ger. Således riskerar prostatacancerpatienten idag förutom en risk för 
överbehandling dessutom att drabbas av postoperativ morbiditet i form av inkontinens och 
erektil dysfunktion. Genom att minska komplikationsriskerna kan man tillåta en högre grad 
av överbehandling. 
Radikal prostatektomi syftar till att avlägsna hela prostatan och därmed avlägsna tumören 
radikalt. Operationstekniken ska vara så atraumatisk som möjligt för att minska riskerna för 
komplikationer till operationen. Operationstekniken har förbättrats med ökande erfarenhet 
och risken för patientskador har blivit lägre. I slutet av 90-talet introducerades laparoskopisk 
operationsteknik av radikala prostatektomier i Frankrike.115 Förhoppningen var då att man 
genom den nya metoden skulle minska morbiditeten av den kurativa kirurgin. År 2000 
genomförde Binder i Tyskland den första robotassisterade radikala prostatektomin i 
världen.120 Robottekniken skulle ge ytterligare bättre resultat p.g.a. en bättre visualisering av 
operationsområdet via bättre ljussättning samt en tredimensionell bild i buken. 
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Robotinstrumenten har dessutom en ökad rörlighet i jämförelse med de konventionella 
laparoskopiska instrumenten som möjliggör en mer exakt dissektionsteknik. Den 
kärlnervsträng som försörjer erektionen ligger an mot prostatakapseln och bör bevaras för att 
bibehålla potensen efter operation. Robotteknikens goda visualisering och utökade rörlighet 
möjliggör sannolikt detta på ett bättre sätt än vid öppen kirurgi. Tekniken gör det även lättare 
att visualisera uretra samt att sy en anatomiskt korrekt anastomos utan att skada den yttre 
miktionssfinktern, vilket tros leda till minskad postoperativ inkontinens. Utöver bättre 
visualisering och mer exakt dissektionsteknik så kommer man med robottekniken lättare åt 
nere i det lilla bäckenet där utrymmesbrist föreligger. I amerikanska operationsmaterial med 
robotassisterad teknik kunde man tidigt visa goda resultat med låga frekvenser av erektil 
dysfuntion, inkontinens samt en hög tumörradikalitet.138,217  
Idag finns det inga högkvalitativa publicerade studier där de olika operationsmetoderna 
jämförs. Trots detta har många valt att satsa på den robotassisterade tekniken och den 
används i allt större utsträckning, utifrån lovande preliminära rapporter både avseende 
postoperativ morbiditet samt onkologiskt resultat. I USA utförs idag ca 85 % av alla radikala 
prostatektomier med robotteknik. I Sverige gjordes 65% av alla prostatektomier med robot år 
2013. Med tanke på den ökade användning av robottekniken föreligger ett stort behov av 
evidensbaserade data som styrker att detta är en lika bra eller bättre metod än den 
konventionella öppna tekniken. Med anledning av detta startade ett samarbete mellan 
Sahlgrenska Universitetssjukhuset samt Karolinska Universitetssjukhuset 2007 då man 
påbörjade en prospektiv icke-randomiserad, öppen jämförande studie av robotassisterad 
laparoskopisk och öppen radikal prostatektomi, LAPPRO. Studien avser att utvärdera den 
robotassisterade tekniken avseende onkologiskt och funktionellt resultat samt även 
patientupplevd livskvalitet och ekonomiska aspekter. Hypotesen var att robotassisterad teknik 
medför en lägre andel komplikationer avseende inkontinens och impotens utan att påverka 
det onkologiska resultatet. Studien ligger till grund för tre av avhandlingens fyra arbeten 
(Studie II-IV). 
Studie I 
Den första studien baseras på 1411 män med prostata cancer som opererades på Karolinska 
Universitetssjukhuset mellan år 2002 och 2006. Studien visar att män besväras kraftigt av 
urinläckage som uppstår efter operationen och att även små mängder läckage är mycket 
besvärande. Definitionen av kontinens brukar baseras på hur många droppskydd patienten 
använder, t.ex. ≤1 skydd/dag. Denna studie visar att antalet droppskydd som männen 
använder varierar mycket oberoende av mängden urinläckage vilket gör att droppskydd är ett 
dåligt mått för att definiera kontinens. Bedömningen skulle bli enklare om definitionen av 
kontinens var "inga droppskydd".  
Studie II 
Den andra studien baseras på data från LAPPRO studien med de patienter som inkluderades 
under de första 17 månaderna. Studien visar att hög ålder vid operation för prostata cancer 
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ger högre risk för inkontinens 1 år efter operationen. Risken stiger exponentiellt med åldern. 
Patienter som uppger att de läcker innan operationen har en ökad risk för inkontinens efter 
operationen. Ytterligare 36 faktorer undersöktes inklusive högt BMI och tidigare transuretral 
resektion av prostatan och ingen av dessa gav någon statistiskt säkerställd ökad risk för 
inkontinens efter operationen.  
Studie III 
Den tredje studien baseras på data från LAPPRO studien och visar att män opererade med 
robotassisterad teknik hade mindre blödning under operationen och kortare vårdtid jämfört 
med män opererade med den öppna tekniken som i sin tur hade en kortare operationstid. 
Reoperation under vårdtiden var vanligare hos män som opererades med öppen teknik och 
dessa patienter sökte även sjukvård oftare under de tre första månaderna efter operationen 
jämfört med män som opererades med robottekniken. Det var ingen skillnad mellan 
grupperna i hur ofta patienterna återinlades på sjukhus inom tre månader efter operationen.  
Studie IV 
Den fjärde studien baseras på data från LAPPRO studien och visar lymfkörtelutrymning vid 
radikal prostatektomi är associerat med en kraftigt ökad risk för djup ventrombos och 
lungemboli. Risken var ännu större vid operation med öppen teknik jämfört med 
robotassisterad teknik. Risken för djup ventrombos och lungemboli ökade om patienten hade 
haft en tidigare propp eller hade en högrisk prostatacancer. Studien visade även att 
lymfkörtelutrymning ökar risken för att patienten återinläggs på sjukhus inom tre månader 
efter operationen.  
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